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1. INTRODUCTION 
Since the early 19th century, it has been discovered that many substances could 
be crystallized into solids having different melting points and crystal habits 
depending on the conditions of crystallization. The term “polymorphism” is 
referred to as a phenomenon where a solid substance can exist in structures 
characterized by different unit cell (i.e., the smallest three-dimensional volume 
element from which crystals can be built), and where each of the forms (poly-
morphs) consist of exactly the same elemental composition (Brittain, 2009). 
Hereby, polymorphs are different crystalline forms of the same pure chemical 
compound.  
Today, an estimated 40% of approved drugs are poorly water-soluble and 
nearly 90% of developmental pipeline consist of poorly water-soluble mole-
cules (Loftsson and Brewster, 2010). Many poorly water-soluble active pharma-
ceutical ingredients (APIs) can exist in different polymorphic or solvated crystal 
forms and also in the amorphous state. Solid-state form and the corresponding 
transformations of API may have a significant influence on the physicochemi-
cal, pharmaceutical and biopharmaceutical properties, e.g. solubility, dissolution 
rate and bioavailability of API, and this can be a serious problem to achieving 
the desired concentration of API in systemic circulation after administration for 
a pharmacological response (Brittain, 2009; Grant, 1999). The amorphous form 
of API has usually an enhanced dissolution and bioavailability compared to the 
crystalline state, but this state is the least stable form of API (Vippagunta et al., 
2001). It is also well known that amorphous forms of APIs show a strong 
propensity to crystallize out very quickly (Lohani and Grant, 2006; Yu, 2001).  
To improve the stability of amorphous form of API, there are many possi-
bilities. One example is the development of amorphous solid dispersion (SDs) 
formulations. SDs are mainly two-component API-polymer binary systems. In 
amorphous SDs usually amorphous drug particles are dispersed in a hydrophilic 
carrier matrix composed of one or more polymers (Brouwers et al., 2009; 
Huang and Dai, 2014). SDs are very promising approach to improve the API 
solubility. But they have some disadvantages, since there is the possibility that 
during processing (mechanical stress) or storage (temperature and humidity 
stress), the amorphous state may recrystallize. This may result in decreased 
solubility and dissolution rate (Vasconcelos et al., 2007). 
Electrospinning (ES) is a versatile, reproducible, continuous and scalable 
technology for the preparation of nanofibers from polymer solution. The major 
advantages of ES include (1) the capability of producing very thin fibers to the 
order of few tenths or hundreds nanometers with a large surface area, (2) ease of 
functionalization for various purposes and (3) superior mechanical properties. 
The wide variety of used polymers and simplicity of the process makes this 
technique very attractive for many different applications, including drug deli-
very (Agarwal et al., 2008; Rošic et al., 2012b). The ES technology combines 
the SD fabrication technology with the nanotechnology, and hence ES could 
also be a potential novel technique for stabilizing the amorphous state of API in 
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a mixture with different polymers. As a versatile process, ES gives us also the 
possibility to develop both immediate and/or controlled-release (CR) drug deli-
very systems for poorly water-soluble drugs (Li and Wang, 2013; Wendorff et 
al., 2012). 
The main objectives of this thesis was to gain understanding of the amorphi-
zation and physical stabilization of a poorly water-soluble API (piroxicam as a 
model API), to evaluate the validity of ES as a novel technique in fabricating 
the high-energy amorphous solid dispersions (SDs) of a poorly water-soluble 
API, and to gather detailed information on the physicochemical, geometrical 
and dissolution properties of such nanofibrous SDs. 
13 
2. LITERATURE REVIEW 
2.1. Solid-state forms 
The chemists found already in the 19th century that crystals of the same substan-
ce can have different properties, and in the beginning of the 20th century (Groth, 
1906–1919) published a five-volume manuscript about such crystals. More than 
fifty years later, McCrone (1965) and Haleblian & McCrone (1969) first pointed 
out the importance of polymorphism in chemistry and especially its usefulness 
in pharmacy.  
Pharmaceutical solids (APIs and excipients) can be crystalline or amorphous. 
In the crystalline state, the constituent molecular units are regularly arranged 
into a fixed and rigid repeating array in crystal lattice, whereas the amorphous 
state consists of disordered arrangements of molecules and does not possess a 
distinguishable crystal lattice (Grant, 1999; Petit and Coquerel, 2006). Crystal-
line solids can exist in the form of polymorphs, solvates or hydrates. Poly-
morphism (Greek: poly = many; morphē = form) is characterized as the ability 
of an API to exist as two or more crystalline phases (polymorphs) that have 
different structural arrangements and/or conformations of the molecules in the 
crystal lattice (Bernstein, 2002; Grant, 1999). Therefore, crystalline polymorphs 
have the same chemical composition but different internal crystal structure, thus 
possessing also different physicochemical properties (Vippagunta et al., 2001). 
Solvates are crystalline forms that include solvent molecules in their crystal 
structure. If the incorporated solvent is water, then solvates are called as hyd-
rates (Morris, 1999). Solvates and hydrates are also referred as pseudopoly-
morphs (Bernstein, 2002; Griesser, 2006; Morris, 1999), and more recently also 
a new term “solvatomorph” has been proposed (Brittain, 2012; Brittain et al., 
2009; Seddon, 2004). 
Today, we know that polymorphism is very common among APIs, and it is 
estimated that approximately one-third of organic compounds and about 80% of 
marketed APIs exhibit polymorphism under experimentally accessible condi-
tions (Lohani and Grant, 2006). Stahli (2007) concluded in his review on poly-
morphs and co-crystals, that 80–90% of organic compounds can exist in 
multiple crystalline forms (polymorphs, hydrates, solvates). 
Since polymorphs have different internal structure and free energies, they 
have different physicochemical properties like melting point, solubility, dis-
solution rate, etc., and those properties can lead to differences in the bioavaila-
bility and stability (Grant, 1999). Very often only one polymorph has the lowest 
free energy and it is thermodynamically the most stable form. The other forms 
are less stable (also called as metastable forms) and they have a tendency to 
reduce their free energy by transforming into the stable form, and this can affect 
the biopharmaceutical performance of the solid dosage form (Grant, 1999; 
Lohani and Grant, 2006). A well-known example is the case of ritonavir, where 
the formation (precipitation) of a more stable form resulted in the dissolution 
test failures of a semisolid formulation (Chemburkar et al., 2000). Sometimes, 
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however, it is desirable to use a metastable form of an API due to its special 
properties, such as higher bioavailability, better technological behavior during 
grinding and compression, or lower hygroscopicity (Lohani and Grant, 2006). 
 
 
2.2. Amorphous state 
The amorphous solid, defined as non-crystalline solid, has a special status in the 
pharmaceutical drug development, and in the earlier literature it has been con-
sidered as one polymorphic form (Haleblian and McCrone, 1969; Petit and 
Coquerel, 2006). Amorphous state, however, significantly differs from a 
crystalline state, and thus it is currently classified as a distinct solid-state form. 
Solid materials can exist intrinsically in the amorphous state or they may be 
intentionally made amorphous by physical manipulation. The amorphous state 
lacks a definite three-dimensional long-range order, which is characteristic to a 
crystalline material, and the position of molecules relative to one another is 
more random (like in the liquid state). Amorphous solids exhibit typically short-
range order over a few molecular dimensions, and consequently, they have quite 
different physical properties from those of their corresponding crystalline states 
(Hancock and Zografi, 1997). The importance of amorphous pharmaceutical 
solids lies in their pharmaceutically useful properties like higher apparent solu-
bility, higher dissolution rate, and sometimes better compression characteristics 
than the corresponding crystal form. The amorphous solids can be produced by 
standard pharmaceutical processes, including melt quenching, freeze- and 
spray-drying, milling, wet granulation, and drying of solvated crystals (Yu, 
2001). By using these methods, the amorphous solids produced are generally 
physically and chemically less stable than the corresponding crystal form of the 
API (Yu, 2001). Some APIs and excipients are known only or mainly in 
amorphous form, while others require deliberate prevention of recrystallization 
to enter and remain in the amorphous state (Petit and Coquerel, 2006).  
 
 
2.3. Solid-state phase transformations 
As discussed previously, the solid-state phase transformations may result in the 
most stable form with lowest free energy. The solid-state phase transformations 
including solvated and hydrated phases of APIs may also have a profound 
impact on the physicochemical, pharmaceutical and biopharmaceutical pro-
perties, such as solubility, dissolution rate, chemical stability and bioavailability 
of API. Since oral bioavailability of many poorly water-soluble APIs depend 
upon solubility and dissolution rate, the identification and detection of such 
transformations between polymorphic and/or solvate forms of APIs in bulk state 
and pharmaceutical formulations, are important (Brouwers et al., 2009; 
Zimmermann et al., 2009). Several recent reports provide evidence that un-
expected solvent-mediated transformations of APIs may be induced especially 
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during the wet manufacture of pharmaceuticals (Airaksinen et al., 2005; Jør-
gensen et al., 2002; Savolainen et al., 2009; Zhang et al., 2004). Similarly, 
during manufacturing process-induced transformations and related precipitation 
of API may change the expected outcome (Airaksinen et al., 2005; Zimmer-
mann et al., 2009). Furthermore, it has been reported that during dissolution 
testing the solid-state conversion of APIs (e.g. hydrate formation) may occur 
and this can be the reason for the misinterpretation of the results (Aaltonen et 
al., 2006; Koradia et al., 2011).  
 
 
2.4. Piroxicam and its solid-state forms 
Piroxicam (PRX) is a non-steroidal anti-inflammatory drug (NSAID) of the oxi-
cam class that inhibits prostaglandin synthesis. It is widely used to relieve the 
symptoms of painful, inflammatory conditions like arthritis (Martindale, 2011). 
Chemically PRX is 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-
3-carboxamide 1,1-dioxide (Figure 1). It is practically insoluble in water, 
soluble in methylene chloride, slightly soluble in anhydrous ethanol (PhEur, 
2015b). 
 
N
S
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H
O
O O
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Figure 1. Chemical structure of piroxicam (PRX). Modified from the European 
Pharmacopoeia 8.0 (PhEur, 2015b). 
 
 
PRX molecule can exist in different solid-state forms and its polymorphs are 
well documented in the literature (Kogermann et al., 2007; Naelapää et al., 
2012; Nyström et al., 2015; Reck et al., 1988; Sheth et al., 2004a; Vrečer et al., 
1991; Vrečer et al., 2003). PRX is a well-known API that has extensively been 
used as a model substance due its interesting physicochemical properties. PRX 
is classified as a class II drug in Biopharmaceutics Classification System (BCS) 
due to its low aqueous solubility and high permeability (Amidon et al., 1995; 
Gwak et al., 2005; Lombardino and Lowe, 2004). It has a zwitterionic nature 
and it is known to have two pKa values (1.86 and 5.46) (Jinno et al., 2000), 
which contribute to PRX behavior at different pHs (Banerjee et al., 2003). Some 
studies consider PRX as a weak acid with a pKa value 5.3 (Okuyama et al., 
1999). The degree to which PRX is ionized depends largely on the pH of the 
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medium. At pH 1.2 PRX exists as a cation and acts as an acid. At pH 5.6 and 
7.2 PRX is in a neutral/zwitterionic form and can act as an acid or as a base in a 
solution. This behavior is obviously due to its oppositely charged -NH2 
and -COOH groups which possesses a large intramolecular multipole moment 
(Banerjee et al., 2003; Gwak et al., 2005; Jinno et al., 2000). Interestingly, the 
PRX crystalline forms have also color differences, and hence its structural solid-
state changes are easily observed. PRX anhydrate form I (PRXAH) exists as 
colorless single crystals irrespective of the polymorphic forms. The amorphous 
form is pale yellow and PRX monohydrate (PRXMH) crystals have rich yellow 
color (Sheth et al., 2005; Vrečer et al., 1991; Vrečer et al., 2003). 
 
 
2.5. Solid dispersions 
2.5.1. Definition 
Today, in pharmaceutical technology the term ‘solid dispersion’ (SD) is often 
used to describe all systems in which an API is dispersed in an inert excipient 
carrier. These systems include also solid solutions where the API exists as a 
molecular dispersion with no discernible second phase (Miller et al., 2008). The 
API in SD can be dispersed as separate molecules, amorphous particles, or 
crystalline particles in the carrier which can be in the amorphous or crystalline 
state (Miller et al., 2008; Vasconcelos et al., 2007; Vo et al., 2013). 
 
 
2.5.2. Advantages and disadvantages of solid dispersions in 
formulating poorly water-soluble drugs 
Formulation of SDs is very fruitful approach in improving the release rate and 
oral bioavailability of poorly water-soluble APIs (Brouwers et al., 2009; Jans-
sens and Van den Mooter, 2009). The first description of SD was published in 
1961 by Sekiguchi and Obi, who reported the formation of a solid solute (mole-
cularly dispersed API in a solid solvent). The authors proposed the formation of 
a eutectic mixture of a poorly water-soluble API and easily water-soluble 
biologically inert carrier. The eutectic mixture was prepared by melting the 
physical mixture of the API and carrier, followed by a rapid solidification 
process. More recently, the eutectic mixtures have been reported to significantly 
improve the solubility of poorly water-soluble APIs and they have shown an 
enhanced absorption after oral administration (Sekiguchi and Obi, 1961; 
Sekiguchi et al., 1964; Serajuddin, 1999; Vasconcelos et al., 2007). The present 
SD systems are defined in the literature as “the dispersion of one or more active 
ingredients in an inert carrier matrix at solid state prepared by melting (fusion), 
solvent, or melting-solvent method”(Chiou and Riegelman, 1971).  
The advantages of SDs include reduced particle size (even at the molecular 
level), enhanced wettability and porosity, and changes in API crystalline state 
(vitrification to an amorphous state) (Leuner and Dressman, 2000; Vo et al., 
2013). The major limitations of SDs are related to the physical stability of API 
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in SDs and batch variability in manufacturing. During manufacturing process or 
storage, the amorphous state may recrystallize to different crystal forms. 
Moreover, the effect of moisture can affect the stability of SD, because most of 
the polymers used as excipients are hygroscopic and absorb moisture. This in 
turn may result in a phase separation, crystal growth, conversion from the 
amorphous to the crystalline state, or conversion of a metastable crystalline 
form to a more stable form during storage (Chiou and Riegelman, 1971; Prasad 
et al., 2014; Serajuddin, 1999; Vasconcelos et al., 2007; Wang et al., 2005). 
 
 
2.5.3. Types of solid dispersions and carrier polymers 
Previously, pharmaceutical SDs were produced only by solvent evaporation or 
melt processing methods, but nowadays supercritical fluid and cryogenic 
freezing technologies have also been demonstrated to be applicable for fabri-
cating the SDs (Miller et al., 2008; Serajuddin, 1999; Vo et al., 2013). The 
physical state of the SD will depend on the physicochemical properties of the 
carrier and API, the API-carrier interactions and the preparation method 
(Janssens and Van den Mooter, 2009). The first classification system based on 
the possible physical state of pharmaceutical SDs was introduced by Chiou and 
Riegelman (1971). Depending on the physical state of the carrier material, the 
SDs are divided into crystalline SDs and amorphous SDs. The SDs have also 
been classified into four generations based on their composition (Figure 2) 
(Chiou and Riegelman, 1971; Vo et al., 2013).  
Usually the term SD refers to a group of solid products consisting of at least 
two different components, generally a hydrophilic matrix and a hydrophobic 
drug. The first generation of SDs introduced were eutectic mixtures (also called 
crystalline SDs), where the crystalline API particles were dispersed in the 
crystalline matrix (Chiou and Riegelman, 1971; Dhirendra et al., 2009; Seki-
guchi and Obi, 1961; Vo et al., 2013). The API in crystalline SD may also exist 
as amorphous particles or separate molecules (crystalline solid solutions), where 
the drug molecules can replace the carrier molecule in the crystal lattice 
(substitutional crystalline solid solutions) or occupy the interstitial spaces 
between the solvent molecules in the crystal lattice (interstitial crystalline solid 
solutions) (Chiou and Riegelman, 1971; Leuner and Dressman, 2000; Sekiguchi 
and Obi, 1961). Crystalline carriers in the 1st generation of SDs comprise of 
urea (Sekiguchi and Obi, 1961) and sugars as sorbitol and mannitol (Jachowicz, 
1987).  
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The second generation of SDs contains amorphous carriers which are mostly 
polymers (Vo et al., 2013). Amorphous SDs can be classified into fully 
amorphous solid solutions (glass solutions) and fully amorphous solid suspen-
sions, or combination of these two depending on the physical state of the API 
(van Drooge et al., 2006). In amorphous solid solution, the API and amorphous 
carrier are homogeneously dispersed at a molecular level, while amorphous 
solid suspension consists of two separate phases. Amorphous solid suspensions 
are formed when the API has limited carrier solubility or a very high melting 
point. Which one of these two types is obtained depends on the miscibility of 
API and carrier material and on the preparation method (Chiou and Riegelman, 
1971; van Drooge et al., 2006). For formulating the second generation SDs, 
there are available a great number of different amorphous carrier polymers. 
They can be divided into full synthetic polymers as povidone or polyvinyl-
pyrrolidone (PVP), polyethylene glycol (PEG), crospovidone (PVPP), poly-
vinylpyrrolidone-co-vinylacetate (PVPVA) and polymethacrylates, and natural-
origin polymers like different cellulose derivatives, starches (potato or corn 
starch) and sugars (trehalose, sucrose, inulin). Most widely used natural-origin 
polymers are hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose 
(HPC) and hydroxypropyl methylcellulose phthalate (HPMCP) (van Drooge et 
al., 2004; Vasconcelos et al., 2007; Vo et al., 2013).  
The third generation of SDs contains a surfactant carrier, or a mixture of 
amorphous polymers and surfactants as carriers (Vo et al., 2013). These SDs are 
intended to achieve the highest degree of bioavailability for poorly water-
soluble drugs, and they avoid such problems as drug precipitation and recrystal-
lization, thus stabilizing the SD (Chiou and Riegelman, 1971; Craig, 2002; 
Janssens et al., 2007; Karatas et al., 2005; Van den Mooter et al., 2006). The 
inclusion of surfactants in the formulation with polymeric carrier may help to 
prevent the precipitation of an API after dissolution in vivo and/or protect a fine 
precipitate from agglomeration into much larger hydrophobic particles (de 
Waard et al., 2008; Karavas et al., 2007; Pouton, 2006; Yüksel et al., 2003). A 
lot of different surfactants and emulsifiers are used as additives in the third 
generation SDs. The most commonly used surfactants and carriers with surface 
activity are sodium lauryl sulfate (SLS), polysorbates (such as Tween 80 and 
Tween 20), poloxamers (Brouwers et al., 2009; Vo et al., 2013), cholic acid, 
bile salts, cholesterol esters and lecithin (Leuner and Dressman, 2000). 
Recently, Soluplus® graft copolymer has been also shown to be applicable in 
formulating the third generation SDs (Hughey et al., 2013; Nagy et al., 2012). 
The fourth generation of SDs is the recently introduced group of controlled 
release solid dispersions (CR-SD). Thus, the present SDs are applicable in 
formulating the poorly water-soluble APIs with a short biological half-life, and 
they can enhance the solubility of poorly water-soluble drugs and extend the 
drug release in a controlled manner. The polymers used in CR-SDs are in-
soluble or dissolve very slowly in water. The conventional polymers applicable 
in formulating CR-SDs are e.g. ethylcellulose (EC), HPC, some Eudragit® 
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grades, poly(ethylene oxide) (PEO) and carboxyvinylpolymer (Carbopol®) 
(Tran et al., 2011; Vo et al., 2013). 
 
 
2.5.4. Preparation of solid dispersions  
All established fabrication methods of SDs are based on two major physical 
processes – on melting and solvent evaporation.  
 
Melting method 
The melting or fusion method was first used by Sekiguchi and Obi (1961) to 
prepare fast-release SD simple eutectic mixtures. This method is based on 
melting the API within the carrier above the eutectic point followed by cooling 
and pulverization of the obtained product (Sekiguchi and Obi, 1961). Cooling 
leads to supersaturation, but due to solidification the dispersed API becomes 
trapped within the carrier matrix. The process has an effect on the final disper-
sion, and for example the cooling rate and proportion of the drug and carrier 
influence the formation of molecular dispersion (Chiou and Riegelman, 1971; 
Leuner and Dressman, 2000; Sekiguchi et al., 1964). Different cooling and 
solidifying methods of melted mixture are described and used in the literature. 
These processes include, e.g. ice bath agitation (Pokharkar et al., 2006; Seki-
guchi et al., 1964; Yoshioka et al., 1994), stainless steel thin layer spreading 
followed by a cold draught (Chiou and Riegelman, 1969), solidification on petri 
dishes at room temperature inside a desiccator (Owusu-Ababio et al., 1998; 
Verheyen et al., 2002), spreading on plates placed over dry ice (Timko and 
Lordi, 1979), immersion in liquid nitrogen (Yao et al., 2005) and storage in a 
desiccator (Law et al., 2003; Vippagunta et al., 2007).  
One major limitation of melting method is the application of high tempe-
ratures, and consequently, many APIs or carrier materials can be degraded by 
the melting process (Serajuddin, 1999). Another challenge associated with a 
melting method is the incomplete miscibility of API and carrier polymer in a 
molten state to obtain a homogenous mixture (Taylor and Zografi, 1997). To 
avoid the present limitations, some modifications have been introduced to the 
original method. In recent years, a hot-melt extrusion (HME) has become a 
common method for fabricating the SDs, since it is a continuous process, thus 
making it suitable for large-scale production (Crowley et al., 2007; Leuner and 
Dressman, 2000; Repka et al., 2007; Shah et al., 2013; Vasconcelos et al., 2007; 
Vo et al., 2013). By HME the API-carrier mixture is simultaneously melted, 
homogenized, extruded and subsequently shaped for different purposes. An 
important advantage of a HME method over the other melting methods is the 
low residence time of the API and carrier at melting temperature in the extruder 
which reduces the risk of the degradation of thermally labile APIs (Leuner and 
Dressman, 2000).  
The other technologies based on the melting process are melt agglomeration 
(Seo et al., 2003; Vilhelmsen et al., 2005) and patented MeltrexTM SD manu-
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facturing process, where a special twin screw extruder with two independent 
hoppers (in which the temperature can vary over a broad temperature range), is 
used (Vasconcelos et al., 2007; Vo et al., 2013; Vynckier et al., 2014). One 
promising alternative for processing thermolabile APIs is also hot-spin melting, 
where the API and carrier are melted together over an extremely short time in a 
high speed mixer and simultaneously in the same apparatus, dispersed in air or 
an inert gas in a cooling tower (Leuner and Dressman, 2000; Vo et al., 2013). 
 
Solvent evaporation method 
A solvent evaporation method consists of the solubilization of the API and 
carrier in a volatile solvent that is later evaporated (Chiou and Riegelman, 
1971). Usually, the resulting films are pulverized and milled. In this method, the 
main advantage is that the thermal decomposition of APIs or carriers can be 
prevented, since organic solvent evaporation occurs at low temperature (Leuner 
and Dressman, 2000; Paudel et al., 2013; Vo et al., 2013). The main dis-
advantages of this method are mostly connected with the solvent – the price, the 
difficulty of completely removing liquid solvent, the possibility of drug-solvent 
chemical interactions and the difficulty of reproducing crystal forms of drugs 
(Brough and Williams, 2013; Leuner and Dressman, 2000; Paudel et al., 2013; 
Serajuddin, 1999; Vo et al., 2013). 
Tachibana and Nakamura (1965) were the first to dissolve both an API and 
carrier in a joint solvent and then evaporate the solvent under vacuum that 
enabled them to produce a solid solution of highly lipophilic β-carotene in PVP. 
The evaporation method was further developed by Mayersohn and Gibaldi 
(1966). They dissolved griseofulvin and PVP in chloroform, evaporated the 
solvent, and then collected the SD with enhanced dissolution, up to 11 times 
compared to the micronized drug (Mayersohn and Gibaldi, 1966). The term 
“co-precipitate” for the abovementioned SDs was first used by Bates (1969). 
For details, how the solvent evaporation process was further developed and why 
the term “co-precipitate” was later replaced by the term “co-evaporate”, see 
Leuner and Dressman (2000) and some other review articles (Brouwers et al., 
2009; Chiou and Riegelman, 1971; Dhirendra et al., 2009; Huang and Dai, 
2014; Leuner and Dressman, 2000; Tran et al., 2011; Vasconcelos et al., 2007; 
Vo et al., 2013). 
Today, spray-drying and freeze-drying (lyophilization) are the most com-
monly used solvent evaporation methods. The first use of product drying in an 
atomized liquid stream was described in the patent of Percy in 1872 (Paudel et 
al., 2013). Afterwards the method has been greatly developed. Today, spray-
drying involves a solvent evaporation usually by vacuum drying (Karavas et al., 
2006; Wagenaar and Müller, 1994; Wang et al., 2005) or spraying the API-
carrier-solvent mixture into a stream of heated air flow to remove the solvent 
(Karavas et al., 2006; Van den Mooter et al., 2006). An alternative method for 
preparing SDs is to spray an API-carrier-solvent mixture into liquid nitrogen to 
form a suspension, and the suspension is then lyophilized (Costantino et al., 
2002; Leuenberger, 2002; van Drooge et al., 2006). Recently, Paudel et al. 
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(2013) published an excellent overview about the background and develop-
ments of spray drying process.  
The basic freeze-drying (lyophilization) process for preparing SDs consists 
of dissolving the API and carrier in a joint solvent and immersing the mixture in 
liquid nitrogen until it is completely frozen. The frozen solution is subsequently 
lyophilized (van Drooge et al., 2006). 
Supercritical fluid (SCF) technology provides an interesting new alternative 
for formulating the SDs of poorly water-soluble APIs. In the SCF, supercritical 
carbon dioxide is commonly used as a solvent (Muhrer et al., 2006; Sethia and 
Squillante, 2002) or anti-solvent (Palakodaty and York, 1999; Won et al., 2005; 
Wu et al., 2009). The use of supercritical carbon dioxide has many advantages 
since the solvent system is chemically inert, non-toxic and non-flammable. 
Furthermore, the process temperature and pressure can be kept low, which makes 
it an attractive for processing heat labile pharmaceuticals (Won et al., 2005). 
The electrospinning (ES) technology combines the SD fabrication techno-
logy with the nanotechnology. In ES process an API-carrier (usually a polymer) 
solution is pumped through an orifice and then subjected to an electrical field. 
When electrical forces overcome the surface tension of the API-polymer solu-
tion at the air interface, the fibers with a diameter of micron-, submicron- or 
nanoscale are formed. The fiber diameter can be adjusted by the surface tension, 
electrical field, dielectric constant, feeding rate and electric field strength. After 
rapid evaporation of the solvent, fibers are collected onto a collector plate/ 
cylinder, and they can be directly used or milled and further processed (Agarwal 
et al., 2008; Brewster et al., 2004; Rošic et al., 2012b; Sethia and Squillante, 
2002; Verreck et al., 2003b). A wide selection of polymers applicable in ES, 
gives the possibility to fabricate SDs with different properties, e.g. water-
soluble polymers for formulating the immediate release dosage forms and water 
insoluble (biodegradable or non-biodegradable) polymers for controlled release 
applications (Brouwers et al., 2009). 
 
 
2.5.5. Characterization of solid dispersions 
Many powerful analytical methods are available to characterize the physical 
solid-state properties, stability and performance of pharmaceutical SDs (Chiou 
and Riegelman, 1971). The most widely used methods are differential scanning 
calorimetry (DSC), X-ray powder diffraction (XRPD), Fourier transform 
infrared spectroscopy (FTIR), scanning electron microscopy (SEM) and the test 
methods on the release rate of the API (dissolution test) (Chiou and Riegelman, 
1971; Leuner and Dressman, 2000; Vo et al., 2013). The other methods are hot 
stage microscopy, polarization microscopy, the variety of spectroscopic 
methods, like Raman spectroscopy, etc. However, at least a combination of two 
or more methods is recommended to study the physical structure correctly 
(Leuner and Dressman, 2000; Vippagunta et al., 2001). For more details about 
the analytical methods used for the characterization of pharmaceutical SDs, see 
the review of Leuner & Dressman (2000). 
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2.6. Electrospinning 
2.6.1. Electrospinning as a method for the fabrication of nanofibers 
ES is a rapid and versatile technique to fabricate polymeric nanofibers with a 
diameter of some tenths nanometers or submicron level and with a large surface 
to volume ratio (Agarwal et al., 2008; Brewster et al., 2004; Verreck et al., 
2003a). The process of ES, also termed as electrostatic spinning, was first 
introduced by Zeleny in 1914. Later, Formhals introduced many new develop-
ments in the ES process and obtained several patents in the 1930’s and 1940’s 
(Formhals, 1934, 1939, 1943, 1944). Since then, the ES apparatus and under-
standing of the process have developed quickly due to the research interest and 
the potential applications of these nanofibers in various areas. History of the key 
developments and scientists in brief: Simons patented an apparatus for the 
production of ultrathin nonwoven fabrics (Simons, 1966), Taylor studied the jet 
produced from the droplet of a polymer solution (Taylor, 1964, 1969) and 
Baumgarten (1971) demonstrated that the fiber diameter and the concentration 
of the solution are directly proportional. Several reviews (Garg and Bowlin, 
2011; Hu et al., 2014; Huang et al., 2003; Ignatious et al., 2010; Persano et al., 
2013; Schiffman and Schauer, 2008) and books (Li and Wang, 2013; Wendorff 
et al., 2012) describe the history and developments of ES in details.  
The basic idea of ES is that the ultrafine fibers are generated by application 
of a strong electric field between the droplet of solvated or melted polymer and 
a grounded target. When the high electrostatic voltage is applied on a drop of 
polymer solution held by its surface tension at the end of a capillary, then the 
surface of the liquid distends into a hyperbolic cone known as the Taylor cone 
(Taylor, 1964, 1969). Once the voltage applied to the spinneret exceeds a 
critical value (often between 0–30 kV), the electrostatic force overcomes a 
solution surface tension and the thin jet of solution is drawn from the droplet 
and whips out towards the grounded collector. Before reaching the collector, the 
liquid jet elongates, solvent evaporates and ultrafine polymeric fibers are 
formed and collected on the target (Agarwal et al., 2008; Garg and Bowlin, 
2011; Hu et al., 2014; Rošic et al., 2012b; Taylor, 1964; Yu et al., 2009). A 
schematic setup of the ES process is shown in Figure 3.  
 
 
Figure 3. Schematic diagram of an electrospinning setup. Key: A. syringe pump; B. 
syringe; C. polymer solution; D. high-voltage power supply; E. electrode; F. grounded 
collector (the figure from the original publication II). 
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2.6.2. Parameters affecting the electrospinning and  
formation of nanofibers 
According to the literature, many parameters can influence the transformation 
of polymer solutions into nanofibers in the ES process (Bhardwaj and Kundu, 
2010; Brewster et al., 2004; Huang et al., 2003; Mit-uppatham et al., 2004; 
Pelipenko et al., 2012; Rošic et al., 2012a; Rošic et al., 2012b). The parameters 
can be divided into three different classes: (1) solution-related parameters, (2) 
process parameters, and (3) ambient parameters. The most important solution 
properties include e.g. concentration, viscosity, conductivity/ surface charge 
density, surface tension, molecular weight of polymer, volatility of solvent, and 
dielectric constant. The major process parameters affecting ES are the applied 
voltage, feed rate/flow rate, and the distance between a needle tip and collector. 
The ambient parameters include e.g. humidity and temperature. For details 
about the critical parameters affecting ES, see the abovementioned references. 
 
 
2.6.3. Polymers and solvents used for electrospinning 
There are hundreds of synthetic and natural polymers that have been processed 
into nanofibers by ES (Agarwal et al., 2008; Bhardwaj and Kundu, 2010; Chew 
et al., 2006; Huang et al., 2003; Wendorff et al., 2012). If the ES process condi-
tions and solvent are properly selected (i.e. voltage, distance between the 
electrodes, flow rate of solution, viscosity, conductivity) virtually all polymers 
can be electrospun (Agarwal et al., 2008). According to Huang et al. (2003), 
there are about 44 polymers and solvent systems described in the literature for 
ES, and additionally 6 melted polymers. The applications for these systems 
cover e.g. protective clothings, sensors, filters, membranes for the prevention of 
surface-induced adhesion, conductive fibers, optical sensors, cosmetic uses and 
medical uses – for wound healing, tissue engineering, hemostatic agents, 
implantable devices, biomaterial scaffolds and drug delivery systems (DDS) 
(Huang et al., 2003). Agarwal et al. (2008) described in their review the ES of 
nanofibers used for biomedical applications – for tissue engineering and DDS 
applications. To our best knowledge, however, no marketed DDS products are 
available to date based on nanofibers. Electrospun pharmaceutical nanofibrous 
dosage forms may be designed to provide rapid, immediate, delayed, sustained 
or by other way modified dissolution.  
The selection of a carrier polymer for ES is crucial since the type of polymer 
and API-polymer-solvent interactions influence the formation, morphology, 
mechanical properties and drug release of nanofibrous mat (Bhardwaj and 
Kundu, 2010; Chronakis, 2005; Huang et al., 2003; Ignatious et al., 2010; Li 
and Xia, 2004; Teo and Ramakrishna, 2006). For wound healing, natural 
polymers like chitosan (Bhattarai et al., 2005; Geng et al., 2005; Jayakumar et 
al., 2010), silk and silk like polymers (Min et al., 2004; Ohgo et al., 2003), 
collagen, gelatin, elastin and cellulose derivatives (Chew et al., 2006; Wendorff 
et al., 2012; Zahedi et al., 2010) are preferred. They are commonly blended with 
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polysynthetic or synthetic polymers, especially with PEO and poly(capro-
lactone) (PCL) (Chew et al., 2006; Huang et al., 2003). In pharmaceutical 
development, more suitable polymers for ES would be cellulose derivatives like 
HPMC, EC, HPC etc., PVP, poly(ethylene-co-vinyl acetate) (PEVA), polyvinyl 
alcohol (PVA), poly(lactic acid) (PLA), PCL and chitosan (Chew et al., 2006; 
Huang et al., 2003; Li and Xia, 2004; Teo and Ramakrishna, 2006).  
In addition, solvent or solvent system plays a crucial role in fiber formation in 
an ES process. The solution is spinnable when the solubility of polymer or 
polymer blend in solvent is optimal. The polymer concentration influences both 
the viscosity and surface tension of the solution. Important factors are also solvent 
volatility and solvent conductivity (Sill and von Recum, 2008). The frequently 
used solvents for nanofiber preparation are chloroform, dichloromethane (DCM), 
tetrahydrofuran (THF), 2,2,2-trifluoroethanol (TFE), 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP), dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), 
ethanol, methanol, acetone, acetic acid and distilled water (Bhardwaj and Kundu, 
2010; Huang et al., 2003; Kenawy el et al., 2002; Rošic et al., 2012b; Sill and von 
Recum, 2008; Zahedi et al., 2010). Although distilled water would be a favorable 
solvent for fabricating nanofibers intended for biomedical and pharmaceutical 
applications, the polymer solubility often limits the use of it. The addition of a 
volatile organic solvent increases the solvent evaporation rate and decreases the 
distance needed between ES needle and collector (Rošic et al., 2012b).  
 
Hydroxypropyl methylcellulose  
HPMC or Hypromellose (Figure 4) is chemically cellulose hydroxypropyl 
methyl ether [partly O-methylated and O-(2-hydroxypropylated) cellulose] 
(PhEur, 2015a) and the variety of different synonyms and trademark names are 
known like Benecel MHPC, Methocel, Metolose, Pharmacoat, Tylopur, Tylose 
MO, etc. (Rogers, 2009). HPMC is available in several grades that vary in 
viscosity (2% w/w aqueous solution at 20 °C) and extent of substitution. HPMC 
is an odorless and tasteless, white or creamy-white fibrous or granular powder 
with the molecular weight from approximately 10,000 to 1,500,000 Da. It is 
soluble in cold water giving a colloid solution, and practically insoluble in hot 
water, acetone, anhydrous ethanol and toluene (PhEur, 2015a; Rogers, 2009). 
HPMC is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. Depending on the viscosity grade and concentration, HPMC is 
applicable in formulating the sustained or controlled-release drug products 
(Dow, 2015b; Leuner and Dressman, 2000; Paudel et al., 2013). Electrospun 
nanostructures based on cellulose derivatives are potential candidates for 
several applications within the field of pharmaceuticals and as drug delivery 
vehicles (Frenot et al., 2007). Verreck et al. (2003) reported on the applications 
of ES for formulating the nanofibrous DDS of HPMC and poorly water-soluble 
API, itraconazole. The rate of drug release from the nanofibers was found to be 
dependent on the API-to-polymer ratio and fiber diameter (Brewster et al., 
2004; Verreck et al., 2003a).  
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Figure 4. Chemical structure of hydroxypropyl methylcellulose (HPMC). Modified 
from Dow Product Leaflet, 2015 (Dow, 2015a). 
 
 
Polyvinyl caprolactam – polyvinyl acetate - polyethylene glycol graft 
copolymer (Soluplus®) 
Soluplus® (PCL-PVAc-PEG graft copolymer) (Figure 5) is a new pharma-
ceutical excipient with an amphiphilic chemical structure, and originally it was 
designed for preparing the solid solutions of poorly water-soluble APIs by HME 
technology (Basf, 2010). Soluplus® is a water-soluble copolymer with the 
average molecular weight ranging from 90,000 to 140,000 Da. It is capable to 
solubilize poorly water-soluble APIs in aqueous media, and to improve signi-
ficantly the bioavailability of these APIs (Basf, 2010; Hardung et al., 2010). It 
has also been used as a binder in wet and dry granulation (Basf, 2010). So far, 
the use of Soluplus® in ES has been very limited, and only little information is 
available in the literature. Nagy et al. (2012) compared electrospun and 
extruded Soluplus®-based oral solid dosage forms for improving the dissolution 
of a poorly water-soluble APIs. More recently, Stranska et al. patented a new 
process of manufacturing of drug products using ES technology, and this 
approach included also Soluplus® graft copolymer combined with Ticagrelor, 
Telaprevir or Aprepitant as poorly water-soluble APIs to obtain the DDSs with 
an amorphous API (Stranska et al., 2014).  
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Figure 5. Chemical structure of Soluplus® (polyvinyl caprolactam - polyvinyl acetate - 
polyethylene glycol graft copolymer, PCL-PVAc-PEG) (IV).  
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2.6.4. Characterization of electrospun nanofibers 
The determination of nanofiber morphology and geometric properties such as 
fiber diameter, diameter distribution, fiber orientation, have been performed 
with different microscopic techniques and instruments such as SEM, field 
emission scanning electron microscopy (FESEM), transmission electron micro-
scopy (TEM) and atomic force microscopy (AFM) (Chung et al., 2009; Ding et 
al., 2002; Huang et al., 2003; Li et al., 2002; Megelski et al., 2002; Pelipenko et 
al., 2013; Srinivasan and Reneker, 1995; Taepaiboon et al., 2006; Tan and Lim, 
2005). There are some problems especially to determine the geometric pro-
perties of single nanofibers and the porosity of nanofibrous mats because of the 
small size and random orientation of the individual fibers. Recently, Janković et 
al. (2013) evaluated successfully the morphology and mechanical properties of 
single electrospun nanofibers by means of AFM. The nanofibers were intended 
for the specific tissue scaffold applications (Janković et al., 2013). Some of the 
polymer nanofibers, however, are challenging to characterize with respect to 
their mechanical and geometric properties since mechanical contact or thermal 
mismatch may lead to the permanent deformation of the fibers (Jayaraman et 
al., 2004; Naraghi et al., 2007; Tan and Lim, 2006).  
The physicochemical characterization of polymeric nanofibers at a mole-
cular level can be performed by FTIR and nuclear magnetic resonance (NMR) 
spectroscopy techniques (Huang et al., 2003). For solid-state characterization, 
thermoanalytical methods (such as DSC), XRPD, vibrational spectroscopy 
(FTIR, Raman), and SEM are known as the most important methods (Brewster 
et al., 2004; Garg and Bowlin, 2011; Huang et al., 2003; Ignatious et al., 2010; 
Jannesari et al., 2011; Kenawy et al., 2009; Kenawy el et al., 2002; Nagy et al., 
2012; Verreck et al., 2003a). 
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3. AIMS OF THE STUDY 
The overall goal of this thesis was to gain understanding of the amorphization 
and physical stabilization and dissolution behavior of poorly water-soluble piro-
xicam (PRX) and its corresponding solid dispersions (SDs) fabricated by means 
of electrospinning (ES).  
 
The specific aims were: 
‒ to evaluate the validity of ES as a novel technique for preparing high-energy 
amorphous SDs of a poorly water-soluble drug PRX, and for fabricating the 
CR-SD nanofibers of PRX and hydrophilic carrier polymers (II, IV) 
‒ to evaluate the validity of scanning white light interferometry (SWLI) as a 
potential novel method for rapid, non-contacting and non-destructive three-
dimensional (3D) topographic analysis of electrospun drug-loaded nano-
fibrous mats without sample preparation (III) 
‒ to reveal the effects of hydrophilic carrier polymers, especially a new 
synthetic graft copolymer PCL-PVAc-PEG (Soluplus®) and solvent systems 
to the solid-state properties and physical stability of drug-loaded nanofiber 
systems (II, IV) 
‒ to gain understanding of the effect of pH on the solubility and dissolution 
rate of two solid-state forms of PRX [anhydrate (PRXAH) and monohydrate 
(PRXMH), respectively] (I) 
‒ to gain understanding of the drug release and dissolution behavior of poorly 
water-soluble PRX from electrospun polymeric nanofibrous mats (II, IV) 
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4. MATERIALS AND METHODS 
A more detailed description of materials and methods is given in the original 
publications which are referred to by their respective Roman numerals (I–IV). 
 
 
4.1. Materials 
4.1.1. Raw materials (I–IV) 
Piroxicam (anhydrous PRX form I, PRXAH I, Letco Medical, Inc. USA) was 
used for dissolution experiments and as a poorly water-soluble model drug in 
electrospun nanofibers (I–IV). The carrier polymers used in nanofibers were 
hydroxypropyl methylcellulose (HPMC) Methocel™ K100M premium CR 
kindly gifted from The Dow Chemical Company, USA (II) or from Colorcon 
Ltd, U.K. (III), and Soluplus® (PCL-PVAc-PEG) kindly gifted from BASF SE 
Pharma Ingredients & Services, Germany (III, IV).  
The primary solvents applied in the ES studies were methanol (Sigma-
Aldrich C.C., Inc.) ethanol, acetone, 2-propanol and dichloromethane (DMC) 
(Lach-Ner, s.r.o., Czech Republic) (II–IV) and 1,1,1,3,3,3-hexa-fluoro-2-
propanol (HFIP) (II, III) (≥ 99.0%) (Sigma-Aldrich C.C., Inc.). All other 
reagents and solvents used were of analytical grade and were used without 
further purification. Distilled water was used in all dissolution experiments (I, 
II, IV). Materials for buffer solutions (KCl, HCl, Na2HPO4, NaH2PO4) were 
obtained from Sigma-Aldrich C.C., Inc. Hard gelatin capsules size 1 (Elanco 
Products Co, Inc.) were manually filled and weighed before and after capsule 
filling, and subsequently used in the dissolution studies (I, II, IV). 
 
 
4.1.2. Preparation of piroxicam solid-state forms (I) 
Prior to dissolution experiments, the initial PRX solid state form was a mixture 
of PRX forms I and II confirmed by means of XRPD (I). Pure anhydrous PRX 
form I (PRXAH) was prepared by dehydrating PRX monohydrate (PRXMH) at 
157 °C. PRXMH was prepared by recrystallization from hot saturated water 
solution as described by Kogermann et al. (2007). All samples were passed 
through a 150-µm sieve prior to experiments (I). 
 
 
4.2. Methods 
4.2.1. Electrospinning (II–IV) 
A schematic diagram of the ES process is shown in Figure 3. The automatic 
syringe pump KdScientific (Model No: KDS-250-CE, Geneq Inc, USA) with a 
pumping speed from 1 to 2 ml/h, was used for ES (II–IV). The high-voltage 
power supply Gamma High Voltage Research (Model No. ES3OP-10W/ DAM, 
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USA) was applied for generating the voltage of 7–22 kV used in the experi-
ments. The distance between the spinneret and the fiber collector was in a range 
of 8–25 cm. For preparing the nanofibers containing HPMC K100M CR as a 
carrier polymer (0.8% solution) and HFIP as a solvent system, the drug-polymer 
(PRX/HPMC) ratios (w/w) were 1:1, 2:1 and 4:1 (II, III). The levels for the 
voltage and distance were 7, 9, 10 kV and 8, 10, 12 cm, respectively. For PRX-
Soluplus® nanofibers [drug-polymer ratio 1:13 (w/w), 33% (w/v) solution in 
acetone], the voltage of 9 kV was used (IV). The distance between the spinneret 
and the fiber collector plate was 10 cm. For preparing other nanofibers, the 
higher operating voltage of 22 kV and distance of 25 cm were applied. 
The electrospun nanofibers were investigated immediately after fabrication 
and within regular time periods during a short-term (until 6-month) aging at a 
low temperature [6 ± 2 °C / 0% relative humidity (RH)] and room temperature 
(22 ± 2 °C / 0% RH). In addition, some samples were also stored for up to 2 
months at higher temperature and humidity conditions (30 °C / 85% RH) (II), 
and some samples were stored even up to 1 year in room conditions (20–23 °C) 
and RH 20–50% (unpublished data). 
 
 
4.2.2. X-ray powder diffraction (I–IV) 
The XRPD patterns of all materials and electrospun nanofibers (immediately 
after fabrication and after a short-term aging) were obtained by using a X-ray 
diffractometer (D8 Advance, Bruker AXS GmbH, Germany) (I–IV). Crystal 
structures were verified by comparing the experimental results to the theoretical 
patterns in the Cambridge Structural Database (CSD) or to the diffractograms 
available in the literature. For PRXAH I and PRXMH, the CSD reference 
crystal structures under refcode BIYSEH (Reck et al., 1988) and CIDYAP01 
(Bordner et al., 1984) were used, respectively. PRXAH forms II and III struc-
tures were compared to the diffractograms reported by Kogermann et al. (2011) 
and Vrečer et al. (2003). The XRPD experiments were carried out in a sym-
metrical reflection mode (Bragg-Brentano geometry) with CuKα radiation (1.54 
Å). The scattered intensities were measured by using a LynxEye one-dimen-
sional detector with 165 channels. In the original publication I, the scanning 
steps of 0.01° 2θ from 3 to 50° 2θ and a total counting time of 8.8 s per step 
were used. In the other papers (II–IV), the angular range was from 5o 2θ to 30o 
2θ with the steps of 0.2o 2θ. The operating current and voltage were 40 mA and 
40 kV, respectively (I–IV). 
 
 
4.2.3. Raman spectroscopy (I, II, IV) 
Raman spectra were collected using a Raman spectrometer equipped with a 
thermoelectrically cooled charge-coupled detector, CCD (1024×64) and a fiber 
optic probe (B&W TEK Inc., USA). A 300-mW laser source at 785 nm was 
used (B&W TEK Inc., USA). Spectra were recorded between 200 and 
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2200 cm-1 with an integration time of 10 s (I) and 12 s (II, IV), and as the 
average of three scans. BWTek software (BWTek, Inc., Newark, USA) was 
used for the collection of Raman spectra. Raman spectra were normalized and a 
spectral region from 1000 to 1700 cm-1 was used for analysis. 
In situ Raman spectroscopy was performed using the same Raman spectro-
meter. The integration time was 1 s. Each spectrum was the average of 3 scans. 
During the slurry experiments the spectra were collected with an interval of 5 
minutes during the time period up to 8 hours (I). 
 
 
4.2.4. Scanning electron microscopy (I–IV) 
The morphology and particle size of PRX powder samples and the diameter and 
surface morphology of nanofibers were investigated with a high-resolution 
SEM (HeliosTM NanoLab 600, FEI Company, USA) (I–III). A measurement 
function of the microscope driving program xT Microscope Control (FEI) was 
applied for the dimensions measurements (I–III). In addition, a high-resolution 
SEM by Zeiss EVO® 15 MA (Germany) was used to investigate the diameter of 
fibers and surface morphology of nanofibrous DDSs (IV). All samples were 
mounted on aluminum stubs with silver paint and magnetron sputter coated with 
a 3-nm gold layer in argon atmosphere prior to microscopy (I–IV). The pro-
gram ImageJ was used for measuring the nanofiber diameter and diameter 
distribution (II–IV). 
 
 
4.2.5. Scanning white light interferometry (III) 
The geometric properties and 3D surface topography of nanofibers and nano-
mats were characterized by scanning white light interferometry (SWLI). In 
SWLI, a light beam passes through an interferometric objective (Nikon, Michel-
son type, magnification 120×) containing a beam splitter that reflects half the 
incident beam onto a reference surface and that passes the other half onto the 
test surface (III, Fig. 2). Light reflected from the test and reference surfaces 
recombines and interferes, forming an interferogram. The objective is translated 
horizontally (scanning) and several interferograms are sequentially imaged. For 
each camera pixel, the modulation signal is extracted from the intensity signal 
as the optical path difference seen through the objective’s focus varies. The 
peak of the modulation signal is detected, and a measurement of relative surface 
height at that point is produced. The modulation signal is periodic for white 
light sources and is, therefore, not subject to the ambiguity problems that affect 
phase measurement methods. The technique can measure rough surfaces and 
several millimeter long steps. The height data are calculated from the inter-
ference data with a nanometer resolution. For details about the method and 
mathematical algorithms used for the data transformation see Larkin (1969), 
Kassamakov et al. (2007, 2009) and Hanhijärvi et al. (2010). In the current 
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research we obtained 3D images featuring 29 nm by 29 nm active pixel size 
from a 55 x 40 μm2 area. 
 
 
4.2.6. Differential scanning calorimetry (II, IV) 
Thermal properties of the starting materials, their physical mixtures and electro-
spun nanofibers were studied using a differential scanning calorimeter, DSC 
(DSC 4000, Perkin Elmer Ltd, Shelton, CT, USA). The DSC system was calib-
rated for temperature and enthalpy using indium as a standard. Samples of 2– 
3 mg were sealed in an aluminium pan with 2 pinholes in a lid. In case of pure 
PRX, the sample size of 0.2 mg was used to be comparable with the other 
samples tested. A nitrogen purge with a flow rate of 20 ml/min was used in the 
furnace. The scans were obtained by heating from 30 °C to 220 °C at a rate of 
20 °C/min. Each run was performed in triplicate. Temperatures are shown as 
on-set temperatures of the events unless mentioned otherwise. 
 
 
4.2.7. Dissolution tests (I, II, IV) 
Dissolution tests were carried out in a semi-automated dissolution system 
(Termostat-Sotax AT7, Sotax, Switzerland) according to United States Pharma-
copoeia 28 (USP28-NF23, 2005) basket method (I, II, IV). Hard gelatin 
capsules (size 1) were manually filled with 20 mg of PRX (either PRXAH or 
PRXMH) (I) or with calculated amount of nanofibers (II, IV) or with physical 
mixture of excipients and API for comparison tests (II, IV). All capsules were 
weighed before and after capsule filling. The dissolution studies were also 
carried out with the nanofibers freely set into the dissolution baskets (II, IV). 
The concentration of PRX in the dissolution medium was measured at 354 nm 
by using an UV-Vis spectrophotometer (Ultrospec III, Biochrom Ltd, UK). The 
dissolution medium was 900 ml buffer solution [distilled water, buffers with pH 
1.2 (HCl/KCl buffer solution) or pH 7.2 (phosphate buffer solution)] maintained 
at 37 ± 0.5 °C as described in the USP 28 (I, II, IV). The pH of the buffer 
solutions was confirmed by the pH meter HI 9024 (Hanna Instruments, USA). 
The dissolution rate of PRXAH and PRXMH was investigated for 10 hours at 
50 rpm (I). The dissolution rate of HPMC and Soluplus® nanofibers was 
investigated at similar conditions for up to 6 and 2 hours, respectively (II, IV). 
The samples were filtered through Glass microfibre filters (Whatman® GF/D). 
An aliquot of the release medium (5 ml) was withdrawn at predetermined time 
intervals (every 3 minutes). The method reproducibility was verified by inves-
tigating six (I) or three (II, IV) samples during one dissolution test (and two 
parallels were performed at each dissolution condition). Standard solution was 
prepared using PRXAH in 0.02 M NaOH solution (I, II, IV). 
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5 RESULTS AND DISCUSSION 
5.1. Physical characterization of piroxicam solid-state 
forms and electrospun nanofibers (I-IV) 
5.1.1. Solid-state forms of piroxicam (I) 
The SEM micrographs revealed the different particle size and surface properties 
of the two PRX solid-state forms (Figure 6). PRXMH crystals appeared much 
larger compared to the PRXAH crystals. In addition, PRXMH showed smoother 
surface of the particles. As expected (Bordner et al., 1984; Reck and Laban, 
1990), both solid-state forms showed similar crystal shapes-prisms. The yellow 
color of PRXMH due to the zwitterionic structure (Sheth et al., 2005), simpli-
fied the differentiation of the two PRX solid-state forms.  
 
 
    
 
Figure 6. Scanning electron microscopy (SEM) micrographs of: (A) piroxicam mono-
hydrate (PRXMH) and (B) piroxicam anhydrate form I (PRXAH). Magnification of 
500×. 
 
 
The crystal forms of PRX were confirmed by XRPD and Raman spectroscopy 
(Figure 7), and were in good agreement with the theoretical patterns and 
previously published data (Kogermann et al., 2007).  
A B 
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Figure 7. X-ray powder diffraction (XRPD) patterns (A) and Raman spectra (B) of 
piroxicam monohydrate (PRXMH) and piroxicam anhydrate form I (PRXAH). Theo-
retical XRPD patterns were obtained from Cambridge Structural Database (CSD), 
CIDYAP and BIYSEH for PRXMH and PRXAH, respectively. All XRPD patterns and 
spectra are normalized and offset for clarity. 
 
 
5.1.2. Solid-state properties of piroxicam incorporated into 
electrospun nanofibers (II–IV) 
To date, the behavior and possible solid-state phase transformations of APIs 
during ES are not very well known and understood. According to the literature, 
there are three (Rošic et al., 2012b) or four (Huang et al., 2003) modes how the 
drug can be incorporated in the electrospun nanofibers (Figure 8): (A) The API 
particles (usually in crystal form) are encapsulated in the carrier polymer; (B) The 
API particles are homogenously mixed at the molecular level with a carrier 
polymer to form nanofibers together (solid dispersion, SD); (C) The API is 
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Drug solubility and content in the polymer solution have been shown to be 
important factors affecting the solid-state form and distribution of API in 
electrospun nanofibers (Meinel et al., 2012; Natu et al., 2010; Rošic et al., 
2012b). Since HFIP has high polarity and strong dissolving capability to various 
polymers and APIs, it was considered as the solvent of choice for dissolving 
HPMC and PRX for ES applications (II). HFIP is also miscible with water and 
chemically bond to a carrier polymer; and (D) The API is physically adsorbed 
onto the surface of polymer nanofibers. If the API-loaded nanofibers are con-
sidered as SDs, they can be classified into four generations like established SD 
systems based on their composition (Chiou and Riegelman, 1971; Vo et al., 
2013).  
In our experiments (II–IV), the drug was simply dissolved in the polymer 
solution prior to ES, and the amorphization of PRX was aimed to be facilitated 
by the fast removal of solvent during ES. Consequently, the SD was most likely 
formed by following the mode “B” described in Figure 8. Both polymers used, 
HPMC (II, III) and Soluplus® (IV), acted in electrospun formulations as 
carrier/stabilizer for the amorphization and stabilizer of the supersaturated state 
upon the release of API. 
 
Figure 8. Schematic diagram on the different possibilities of drug loads in/on 
electrospun nanofibers: (A) encapsulated drug; (B) drug-polymer solid dispersion (SD) 
(B1 with crystalline drug; B2 with amorphous drug); (C) chemically bonded drug; (D) 
physically adsorbed drug. Modified from Rošic et al., 2012b and Huang et al., 2003. 
 
36 
many organic solvents, it has low surface tension and it is very volatile, thus 
suggesting applicability in ES (Zhang et al., 2007). PRX was found to be in 
amorphous form in the electrospun nanofibers (with a drug:polymer ratio 4:1) 
(II, III). Volatile acetone was selected for dissolving Soluplus® graft copoly-
mer, since a quick solvent evaporation is essential for the formation of homo-
geneous nanofibrous mats. Acetone is also a cheaper and less toxic solvent than 
HFIP. The amount of PRX dissolved in Soluplus® /acetone solution was many 
times lower than that used in HPMC/HFIP solutions; the ratio of drug:polymer 
was in well spinnable solutions only in weight ratio 1:13 (IV).  
The amorphous form of APIs is physically unstable and has a tendency to 
spontaneously recrystallize (Hancock and Zografi, 1997). PRX is a polymorphic 
drug that may exist in different solid state forms, including three anhydrate (I-
III), monohydrate and amorphous forms (Sheth et al., 2004a; Vrečer et al., 
2003). Recently, a research group from Helsinki found a new, still unidentified 
form of PRX (“form IV”) (Nyström et al., 2015). Therefore, it is very important 
to analyze in which form PRX actually exists in electrospun nanofibers, and 
how stable the present solid-state form is, when stored in different environ-
mental conditions. In this study, XRPD and Raman spectroscopy were used for 
verifying the solid state forms of PRX. 
 
 
 
5.1.2.1. X-ray powder diffraction analysis (II–IV) 
The XRPD analysis verified that prior ES PRX was present as PRXAH with 
characteristic XPRD reflections at diffraction angles 2θ of 8.3°, 11.7°, 12.5°, 
14.3°, and 17.7° (I, II, IV). The cellulose ether polymer (HPMC) and PCL-
PVAc-PEG graft copolymer (Soluplus®) were amorphous polymers without any 
characteristic diffraction reflections in their XRPD pattern (II–IV).  
In our studies, the amorphous halo in all XRPD patterns indicated the 
presence of amorphous PRX (Figure 9 and 10). Hence, XRPD results revealed 
that the nanofibers contained PRX in amorphous form immediately after 
fabrication and after a 3-month (II) or 6-month (IV) aging period (Figure 9 and 
10). The samples were stored at low (6–8 °C) and/or room (22 ± 2 °C) tempera-
ture and low humidity (RH 0%).  
There were no differences between the polymers used and the amount of 
drug loaded into the nanofibers. The PRX was combined with carrier polymer 
HPMC at weight ratios of 1:1, 2:1 or 4:1 as described in the original papers (II, 
III). The XRPD diffraction patterns also suggested that PRX existed in 
amorphous form with no signs of recrystallization or polymorphic solid-state 
changes during the aging in controlled conditions (temperature, humidity).  
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Figure 9. X-ray powder diffraction (XRPD) patterns of piroxicam(PRX)-loaded hydro-
xypropyl methylcellulose (HPMC) nanofibers (a drug-polymer ratio 1:1 w/w) imme-
diately after fabrication and after a short-term aging of the samples at low (LT 6–8 °C / 
0% RH) and room temperature (RT 22 ± 2 °C/0% RH). 
 
 
 
Figure 10. X-ray powder diffraction (XRPD) patterns of crystalline anhydrous piro-
xicam (PRX) forms and nanofibers of Soluplus® graft copolymer loaded with PRX: (A) 
PRXAH form I; (B) PRXAH form II; and (C) fresh and aged drug-loaded nanofibers of 
PRX and Soluplus® (a drug-polymer ratio 1:13 w/w). 
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According to Kogermann et al. (2011), the spontaneous recrystallization of 
amorphous PRX starts within few minutes after the amorphous form pre-
paration leading to the formation of PRXAH I. Our results suggest that the ES 
of PRX with HPMC in HFIP or with Soluplus® in acetone clearly prevents the 
solid-state transformation (recrystallization) of PRX, and consequently, stabili-
zes the amorphous form of PRX in the solid formulation. However, it is known 
that HPMC has the ability to form hydrogen bonds between drug molecules and 
the polymer, and consequently, to increase the activation energy for crystal-
lization (Brouwers et al., 2009). Soluplus® is a relatively new amphiphilic graft 
copolymer that has been introduced to the pharmaceutical industry for the 
purpose of solubilizing poorly water-soluble APIs. This polymer is capable to 
form SDs with poorly water-soluble APIs and to prevent the rapid hydration of 
compacts with the tendency to form a strong gel at the surface (Hughey et al., 
2013). Soluplus® has shown high affinity or even strong binding with some 
BCS II class drugs in solid solutions during absorption experiments (Linn et al., 
2012). It is evident that the corresponding affinity exists also between PRX and 
Soluplus® in electrospun nanofibers, thus preventing the recrystallization of 
amorphous PRX (II–IV). 
Since the solid-state transformations of drug are dependent on the tempera-
ture and humidity, the aging studies of the HPMC-PRX nanofibers were also 
carried out at elevated temperature and humidity conditions (30 °C / 85% RH) 
(II). The characteristic reflection of PRXAH III at a diffraction angle 2θ of 8.9° 
suggested partial recrystallization of amorphous PRX already after three-day 
aging (Figure 11) (II). When the samples were stored up to 1 year at ambient 
room temperature (20–23 °C) and RH (2050%), it was found that numerous 
crystals of PRX forms were formed along the HPMC nanofibers (Figure 12, 
unpublished data).  
     There are only few reports in the literature on the effects of manufacturing pro-
cess and storage conditions on the physical solid-state stability of amorphous 
form of PRX. (Sheth et al., 2004b) reported that by using a cryogenic ball milling 
some polymorphic memory of PRXAH I could retain in the respective amorphous 
form of PRX. The amorphous form tends to recrystallize predominantly to 
PRXAH I, although some PRXAH III character may also be present. Similarly, 
Naelapää et al. (2012) showed that PRXAH I amorphous samples recrystallized 
as PRXAH I together with the diffractions of the least stable PRXAH III. 
Furthermore, the storage conditions have been shown to influence the amorphous 
state of PRXAH I due to the possible presence of higher residual order in X-ray 
amorphous PRXAH I samples (Naelapää et al., 2012). Our study reveals that the 
recrystallization of amorphous PRX was slowed down in controlled conditions 
(temperature, humidity) by the presence of polymer in the nanofibers. Further 
solid-state changes were also inhibited (II). 
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Figure 11. X-ray powder diffraction (XRPD) 
patterns of piroxicam (PRX) loaded hydro-
xypropyl methylcellulose (HPMC) nanofibers 
(a drug-polymer ratio 1:1) immediately after 
fabrication and after a three-day aging of the 
samples at elevated temperature and humidity 
conditions (30 °C/85% RH). The asterisk (*) 
indicates the main characteristic reflection of 
PRXAH form III (II). 
Figure 12. Scanning electron micro-
scopy (SEM) micrograph of piroxicam 
(PRX) crystals formed inside the hydro-
xypropyl methylcellulose (HPMC) nano-
fibers, when the samples were stored for 
up to 1 year at ambient room temperature 
(RT 20–23 °C) and relative humidity 
(RH 20–50%). 
 
 
 
 
5.1.2.2. Raman spectroscopy analysis (II, IV) 
The Raman spectra of fresh and aged polymeric PRX and HPMC (1:1) nano-
fibers were identical, thus indicating that no solid-state transformations occurred 
during a short-term aging of nanofibers at LT and RT within 3 months (Figure 
13) (II). The joint characteristic peaks for amorphous PRX, are shown at 1159, 
1237, 1331, 1365, 1438, 1477, 1531, and 1561 cm-1. The present Raman 
spectroscopy results were in agreement with the previous Raman spectroscopy 
results (Kogermann et al., 2011) suggesting the presence of amorphous PRX in 
the nanofibers. 
During ES, a large specific surface area is obtained resulting in a fast and 
efficient evaporation of organic solvent. Consequently, molecules have no time 
to (re)crystallize and hence they most likely have an amorphous supermolecular 
structure (Verreck et al., 2003a; Zong et al., 2002). Moreover, a hydrophilic 
polymer (like HPMC) with an ability to form hydrogen bonds can prevent the 
crystal growth of an API by hindering the incorporation of drug molecules into 
a crystal lattice (Brouwers et al., 2009). It is evident, however, that elevated 
storage conditions can induce the recrystallization of amorphous PRX, since 
only three-day aging at 30 °C / 85% RH led to the formation of PRXAH III. 
Interestingly, both Raman spectroscopy and XRPD analyses revealed (data not 
shown) that the nanofibers with a higher drug-polymer ratio of 2:1 and 4:1 were 
amorphous immediately after preparation, but after a two-month aging PRX 
tended to crystallize out from the nanofibers (unlike with the respective 1:1 
samples). This suggests that the amount of HPMC is critical and needs to be 
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high enough to prevent the recrystallization of PRX through forming hydrogen 
bonds in the present electrospun nanofibers. These results highlight the impor-
tance of proper storage conditions which remarkably can change the solid state 
stability of amorphous PRX in the electrospun polymeric nanofibers (II, III).  
 
 
 
Figure 13. Raman spectra of electrospun piroxicam (PRX) loaded hydroxypropyl 
methylcellulose (HPMC) nanofibers (a drug-polymer ratio 1:1) immediately after 
fabrication and after a short-term aging at low (LT 6–8 °C / 0% RH) and room 
temperature (RT 22 ± 2 °C/0% RH). Key: PRXAH I = PRX anhydrate form I; PRXAH 
II = PRX anhydrate form II; PRXAH III = PRX anhydrate form III; and PRXMH = 
PRX monohydrate. The asterisks (*) represent the characteristic peaks for amorphous 
PRX (II). 
 
 
As seen in Figure 14, the electrospun nanofibers of PRX and Soluplus® showed 
similar characteristic Raman spectroscopy peaks for amorphous PRX as were 
observed with the PRX and HPMC nanofibers (at 1237, 1477, 1531 and 1561 
cm-1). Since the amount of PRX in the Soluplus® nanofibers is much lower than 
that in the corresponding HPMC nanofibers, only the peaks with higher 
intensity of amorphous PRX are visible (IV).  
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Figure 14. Raman spectra of physical mixture and electrospun nanofibers of piroxicam 
(PRX) anhydrous form I (PRXAH I) and Soluplus® graft copolymer. Key: (A) 
amorphous form of PRX (B) pure PRXAH I; (C) physical mixture of PRXAH I and 
Soluplus® (1:13 w/w); (D) Soluplus® nanofibers loaded with PRX (1:13 w/w drug-
polymer ratio); (E) pure Soluplus® graft copolymer nanofibers (IV). All spectra are 
normalized and offset for clarity. The asterisks (*) represent the characteristic peaks for 
amorphous PRX. 
 
 
5.1.2.3. Thermal behavior (II, IV) 
The DSC thermograms (Figure 15 and 16) confirmed the presence of PRX in 
amorphous form in the electrospun nanofibrous mats immediately after pre-
paration. The DSC thermogram of pure PRXAH I exhibited a single melting 
endotherm at 204.0 °C (Figure 15 and 16A) with the enthalpy of melting (ΔH) 
100.8 J/g, which is in good agreement with the values reported in the literature 
(Stulzer et al., 2008; Wu et al., 2009) (II, IV). The pure HPMC and non-drug 
containing nanofibers showed the thermal behavior of amorphous material 
without any melting endotherms, just only with small endothermic events in the 
range of 30–110 °C due to the dehydration of polymers (Figures 15B and 15C 
respectively). The pure Soluplus® graft copolymer showed characteristic endo-
therm of glass transition temperature (Tg) at 70–80 °C (Figure 16B), in agree-
ment with the literature data (Basf, 2010). 
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Figure 15. Differential scanning calorimetry (DSC) thermograms. Key: (A) piroxicam 
(PRX) anhydrate form I (PRXAH I); (B) hydroxypropyl methylcellulose, HPMC 
(MethocelTM K100M premium CR), (C) electrospun HPMC polymeric nanofibers and 
(D) electrospun PRX:HPMC nanofibers (a drug-polymer ratio 1:1) (II). 
 
 
In the case of PRX and HPMC nanofibers measured immediately after pre-
paration (Figure 15D), the DSC thermograms of electrospun nanofibers showed 
a weak exothermic event at 131.1 °C (ΔH = -25.1 J/g) suggesting partial 
(minor) recrystallization of amorphous PRX. This observation was confirmed 
by the second endotherm at approximately 199.0 °C, most likely corresponding 
to the PRXAH III melting. In addition, a concomitant reduction in peak size and 
enthalpy per unit mass of PRX was evident (ΔH of PRX decreased from 100.8 
to 50.3 J/g). These results also agree with the XRPD and Raman spectroscopy 
ones. The recrystallization of PRXAH III from electrospun nanofibers upon 
heating enlightens the instability of amorphous PRX at higher temperatures (II). 
The DSC thermographs of PRX-HPMC nanofibers suggest the absence of any 
solid-state interactions or incompatibility between PRX and HPMC. 
As Soluplus® (PCL-PVAc-PEG graft copolymer) has a slightly different 
thermal behavior (Figure 16B), the PRX-loaded polymeric nanofibers pre-
sented a broad evaporation endotherm in a range of 30 ºC–110 ºC and exhibited 
the second (even wider) endotherm ranging from 100 ºC to 220 ºC. This 
suggests that a physical interaction or fusion of PRX into the Soluplus® had 
occurred (IV). Moreover, no thermal events due to the chemical decomposition 
were found (II). Both DSC thermographs (Figure 15D and Figure 16D) 
supported the XRPD and Raman spectroscopy findings suggesting the presence 
of amorphous PRX in the nanofibers. 
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Figure 16. Differential scanning calorimetry (DSC) thermograms of the starting 
materials, physical mixture with Soluplus® (1:13 w/w), and electrospun nanofibers of 
PCL-PVAc-PEG graft copolymer (Soluplus®) loaded with and PRX: (A) pure 
piroxicam (PRX) anhydrous form I (PRXAH I); (B) pure Soluplus® craft copolymer; 
(C) physical mixture of PRXAH I and Soluplus® (1:13 w/w); (D) drug loaded nano-
fibers of PRX and Soluplus® (1:13 w/w) (IV). The arrows shows the Tg of Soluplus® 
(70 °C) and the melting point of PRXAH I (204 °C). 
 
 
5.1.3. Surface morphology, size and size  
distribution of nanofibers (II–IV) 
According to the literature, the morphology and diameter of electrospun nano-
fibers are dependent on the intrinsic properties of the solution such as the type 
of polymer, the conformation of polymer chain, viscosity (or concentration), 
elasticity, electrical conductivity, and the polarity and surface tension of the 
solvent (Li and Xia, 2004; Lu et al., 2009; Meinel et al., 2012). From the pro-
cess parameters the most crucial are the applied voltage, the feed rate and the 
distance to the collector (Rošic et al., 2012b).  
In our studies, different polymers and solvent systems were tested to find the 
most suitable polymer-solvent combinations and optimal process parameters for 
fabricating the nanofibers (II, IV). The morphological properties, size and 
shape of nanofibers were analyzed by high-resolution SEM. The SWLI 3D 
topographic analysis was used for the rapid investigation of geometric para-
meters without any sample preparation.  
The drug-loaded nanomats of polymers (HPMC, Soluplus®) and PRX 
exhibited a 3D layered fiber mesh structure, nonwoven pattern and absence of 
beads. The representative SEM images of the electrospun nanofibers of PRX 
and HPMC, and the reference pure polymer nanofibers (without PRX) are 
shown in Figure 17 (II). The average diameter of the drug-loaded nanofibers 
was slightly larger (387 ± 125 nm, n = 100) than that of the reference polymeric 
nanofibers fabricated from the pure polymer-solvent system (195 ± 143 nm, n = 
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100) (Figure 17). The SEM fiber diameter distributions of electrospun nano-
fibers containing a pure carrier polymer HPMC and HPMC with PRX at weight 
ratios of 1:1, 1:2 and 1:4, are shown in Figure 18 (III). All types of electrospun 
nanofibers (with and without PRX) exhibited very uniform thickness forming a 
homogeneous non-woven nanomat onto a collector plate. 
 
 
 
 
Figure 17. Scanning electron microscopy (SEM) micrographs of electrospun piroxicam 
(PRX) loaded hydroxypropyl methylcellulose (HPMC) nanofibers (a drug-polymer ratio 
1:1) (A, B) and the reference nanofibers of a pure carrier polymer HPMC (C, D). 
Magnification 50,000× (A, C) or 5,000× (B, D) respectively (II). 
 
 
According to Meinel et al. (2012), blending polymer solutions with drugs can 
affect the geometric properties of electrospun fibers due to the changes in 
solution viscosity and electrical conductivity. A decrease in the charge density 
on the surface of the electrospun jet and an increase in solution viscosity result 
in larger fiber size.  
 
A 
C 
B
D 
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Figure 18. The scanning electron microscopy (SEM) diameter distributions of nano-
fibers containing a pure carrier polymer HPMC (without drug), and HPMC and a model 
drug, Piroxicam (PRX) at a ratio of 1:1, 1:2 and 1:4 (III). 
 
 
As seen in Figure 19 (IV), the nanofibers of Soluplus® were circular in cross-
section with an average diameter ranging from 500 nm to 2 μm. The formation 
and presence of defects, such as beads, were not observed suggesting that the 
viscosity and surface tension of the polymeric solution was suitable for 
fabricating the drug-loaded nanofiber matrices. Furthermore, the presence of 
crystallized PRX on the surface of nanofibers was not observed indicating that 
the drug was in a non-crystalline state in the electrospun nanofibers. The XRPD 
and Raman spectroscopy data also verified this finding (II–IV). 
 
 
 
 
Figure 19. Representative scanning electron microscopy (SEM) micrograph of the 
electrospun nanofibers of Soluplus® graft copolymer loaded with a model drug, 
piroxicam (PRX) Magnification 20,000× (IV). 
1𝜇m
Pa 1
Pa 1
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R1 = 648.8nm
Pb 1 = 331.7∘
Pa 2 =
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Several recent studies have demonstrated that the topography and geometric 
properties of the polymeric nanofibrous mats are important variables that affect 
the performance and therapeutic efficiency of the nanomats in pharmaceutical 
and biomedical applications (Chen et al., 2007; Huang et al., 2012; Leung and 
Ko, 2011; Lu et al., 2009; Pelipenko et al., 2013). The morphological 
appearance of the drug-loaded electrospun nanomats has also been reported to 
be dependent on the material variables, i.e. polymer type, the chemical nature 
and molecular weight of the drug(s) (Meinel et al., 2012; Taepaiboon et al., 
2006). A novel SWLI method (used for the first time for characterizing the 
nanofibers) provided a nanometer-resolution vertical insight into the internal 
structure of the polymer nanomats and a quantitative measurement of the 
thickness of the mats. SEM provided high-quality images of the orientation and 
size of the individual fibers in the mats but no quantitative measurement related 
to the vertical fiber layering or thickness of the nanomats. The advantage of 
SWLI is that the method is rapid, non-destructive, non-contacting and it 
provides 3D visualization of small samples. Consequently, SWLI has been used 
e.g. to characterize miniature elements and micro-fluidic devices (Coupland and 
Lobera, 2010; Kassamakov et al., 2009; Kassamakov et al., 2007; Madani-
Grasset et al., 2008). Only few studies report on applying SWLI to characterize 
pharmaceutical systems. Hanhijärvi et al. (2010) measured the surface rough-
ness of pharmaceutical thin films with SWLI, and more recently Genina et al. 
(2012) used this method for describing of flexographic coated controlled-release 
systems.  
Characterizing electrospun polymeric nanofibers is challenging since the 
fibers are small and randomly oriented in the nanomats (usually in a non-woven 
form). A non-woven form of nanofibrous mats is beneficial in many biomedical 
applications, such as in wound dressings and nanofibrous scaffolds for cell 
attachment (Leung and Ko, 2011). We investigated nanofibers with different 
PRX-HPMC ratios (1:1, 2:1, 4:1) by SWLI and SEM, and compared the 
methods and results (III). The SEM image-based measurements showed that the 
average fiber diameter (n =100) was independent of the drug-polymer ratio 
(Figure 18). The SWLI measurements revealed that the API-loaded mats were 
4.0 μm to 4.5 μm thick (uniformly) regardless of the polymer and PRX ratio. 
With increasing PRX concentration, the nanomats became sparser and less 
dense (loose). The diameter and length of individual nanofibers could not be 
accurately measured with the SWLI. The thickness of the mats was determined 
by SWLI from the vertical position of the most dense fiber layer. The SWLI 
thickness of the nanomats was 2.5–3.0 μm (for a PRX and HPMC ratio of 1:1), 
2.0–3.0 μm (for a PRX and HPMC ratio of 2:1), and 2.0–2.5 μm (for a PRX and 
HPMC ratio of 4:1). This suggests that the drug-loaded mats are porous as was 
also shown with the SWLI 3D topographical maps of the mats. The porosity of 
the different surface layers is related to the number of layers present in the mat 
(Ghasemi-Mobarakeh et al., 2007). 
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Figure 20. Scanning white light interferometry (SWLI) three-dimensional (3D) images 
and surface profiles of drug-loaded nanofibrous mats. The model drug piroxicam (PRX) 
and the carrier polymer HPMC ratios were 1:1 (A), 2:1 (B) and 4:1 (C). The sites that 
were profiled are indicated with black lines (III). 
 
 
Figure 20 shows the SWLI fiber architecture and surface profiles (roughness) 
of the API-loaded non-woven nanomats (PRX-HPMC) along randomly selected 
lines crossing the mat surface (III). Cross-over points with individual nano-
fibers can be clearly distinguished in the SWLI profile. The 3D topographical 
maps obtained by SWLI show deep porous structures in the non-woven API-
loaded nanomats. Our study (III) shows usefulness and also some limitations of 
this method to describe the geometric properties and surface topography of 
polymeric nanofibers and nanofibrous mats intended for pharmaceutical and/or 
biomedical applications. 
 
 
5.2. Dissolution behavior (I, II, IV) 
5.2.1. Dissolution of piroxicam solid-state forms (I) 
The discussion about maximum solubility of different PRX forms and pre-
diction of solid-state changes during dissolution tests is presented in detail in 
the original paper I. The solubility and dissolution behavior of APIs are the key 
determinants of drug bioavailability for its intended therapeutic use (Aaltonen et 
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Figure 21. The solubility-time profiles of PRXAH (open symbols) and PRXMH (closed 
symbols) at pH 7.2 (black squares), distilled water pH 5.6 (red circles), and pH 1.2 (blue 
triangles) using 200 mg PRX dose. For clarity purposes, the standard deviation is not 
shown, but for all dissolution results it was below 3.5% (I).  
 
To investigate the effects of biorelevant pH on the solubility and dissolution of 
PRX forms, and consequently, to predict the dissolution behavior in different 
parts of the GI tract, the in-vitro dissolution tests were performed in a simulated 
gastric fluid (pH 1.2), in distilled water and in a phosphate buffer solution (pH 
7.2). According to the results on solubility (Figure 21), both PRX forms have 
the lowest solubility in distilled water (pH 5.6). The highest solubility was 
observed at pH 7.2 (phosphate buffer solution), and both forms showed mid-
solubility values at pH 1.2 (HCl/KCl buffer solution). These results are in 
agreement with the published findings of Jinno et al. (2000) suggesting that the 
best solubility of PRX would be in basic environment.  
In our dissolution studies (Figure 22), the two PRX solid-state forms 
revealed similar trends and pH dependence as observed in solubility testing. 
Small differences could be explained by the differences in the amount of PRX 
al., 2006; Javadzadeh et al., 2005). As stated, PRX is a poorly water-soluble, 
highly permeable class II drug (Amidon et al., 1995), and the rate of oral 
absorption is mainly controlled by the dissolution rate in the gastrointestinal 
tract (GI). The solubility and dissolution of PRX depends also greatly on pH, 
since it has two pKa values and therefore its solubility and dissolution rate 
changes at different pH. Solubility is dependent on the degree of ionization, 
molecular size, interactions of substituted groups with solvent and crystal 
properties. When the pH of an aqueous solution approaches the pKa, there is a 
very pronounced change in the ionization of an API, and consequently in APIs 
solubility and dissolution.  
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used in the solubility and dissolution tests. As shown in our paper I, the solid-
state changes during the solubility testing were observed. The PRX transforms 
to yellow PRXMH during the solubility testing, and this can affect to the 
solubility of PRX. Since the dissolution tests were performed only for 45 
minutes and the amount of used PRX was small (only 20 mg of PRX in 
capsules) the complete solid-state phase transformation was not observed.  
 
 
 
5.2.2. Dissolution of electrospun nanofibers (II, IV) 
According to the literature, the drug release from electrospun polymeric 
nanofibers is dependent on several material and process factors including drug 
molecular weight, loading and state, carrier polymer(s), fiber crystallinity, fiber 
diameter and porosity, and drug-polymer-ES solvent interactions (Meinel et al., 
2012; Natu et al., 2010). The dissolution profiles of PRX loaded in HPMC 
nanofibers, pure PRX powder and physical mixtures of PRX and HPMC at 
different pH conditions, are shown in Figure 23. The dissolution of pure 
PRXAH I was dependent on the pH of dissolution media being poorer in the 
acidic (pH 1.2, Figure 23A) than in slightly basic (pH 7.2, Figure 23B) dis-
solution medium. In the case of PRX and HPMC nanofibers, the release rate of 
PRX shows the controlled release kinetics and interestingly was less dependent 
on the pH of the dissolution media being only slightly lower at pH 1.2 than pH 
7.2. The PRX-HPMC nanofibers behaved as controlled release DDSs, and they 
showed at least half or even more decrease in the release rate compared to that 
of pure PRX. 
 
Figure 22. The dissolution profiles of PRXAH (open symbols) and PRXMH (closed 
symbols) at pH 7.2 (black squares), distilled water pH 5.6 (red circles) and pH 1.2 (blue 
triangles) using 20 mg PRX dose in capsules. For clarity purposes, the standard 
deviation is not shown, but for all dissolution results it was below 1.9% (I). 
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Figure 23. Release profiles of piroxicam (PRX) loaded hydroxypropyl methylcellulose 
(HPMC) nanofibers at (A) pH 1.2 and (B) pH 7.2 (n = 6). For clarity purposes, the 
standard deviation is not shown, but for all dissolution results it was below 5.0% (II). 
 
 
As shown in Figure 23, the electrospun nanofibers loaded in hard gelatine 
capsules exhibited a short lag-time (10–15 min), the absence of initial burst 
release and zero-order linear dissolution kinetics. Sustained-release dissolution 
of the polymeric nanofibers was attributed to a high-molecular HPMC grade 
used as a carrier polymer and the formation of a solid matrix inside hard 
gelatine capsules. According to the literature, the drug release profiles from 
HPMC containing hydrophilic matrices are generally first-order for highly 
water-soluble drugs and zero-order for insoluble drugs (Tran et al., 2011). It is 
evident that the amorphous state of PRX and generation of supersaturated 
solution associated with the present SD nanofibers, decreased the lag-time for 
A 
B 
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the drug release in vitro. In addition, it is expected that SD nanofibers as a kind 
of supersaturating DDS could enhance the absorption of a poorly water-soluble 
drug by reducing the precipitation of drug and thus generating high free drug 
concentrations, e.g. in the gastrointestinal tract. According to Brouwers et al. 
(2009), it is possible that the supersaturation plays a role in the absorption 
process of poorly water-soluble drugs in various solubilizing dosage forms. 
Such dosage forms can be adjusted into the supersaturated formulations by 
using a suitable precipitation inhibitor (e.g. HPMC) in the delivery system.  
Since our recent study suggests that hard gelatine capsule shells might 
interact with a carrier polymer (Kogermann et al., 2013), a number of disso-
lution tests were performed without using hard gelatine capsules (i.e. with free 
nanofibers in the baskets) (Figure 23). The free fibers showed an initial burst 
release and then almost constant prolonged drug release. This differed from the 
dissolution behavior of the nanofibers loaded in hard gelatine capsules (a drug-
polymer ratio 1:1). Figure 24 illustrates the effects of drug-polymer ratio on the 
release profile of PRX loaded nanofibers (free nanofibers in the baskets). The 
dissolution of amorphous PRX from the nanofibers was a prolonged carrier-
polymer controlled process, and the initial dissolution rate of PRX was directly 
connected with a PRX-polymer ratio. By increasing the drug content in nano-
fibers, a greater portion of the drug is evidently located near the surface of the 
nanofibers, and hence initial release of the drug is faster (Figure 24).  
 
 
Figure 24. Effects of drug-polymer ratio on the dissolution behavior of piroxicam 
(PRX) loaded hydroxypropyl methylcellulose (HPMC) nanofibers (n = 6). The 
dissolution behavior of free nanofibers in baskets (with a drug-polymer ratio 1:1 (red) 
and 4:1 (blue) w/w) was tested at pH 1.2 (∆) and 7.2(□). The initial dissolution rate of 
PRX is shown in the small figure. For clarity purposes, the standard deviation is not 
shown, but for all dissolution results it was below 5.0% (II). 
 
52 
The PRX-Soluplus® nanofibers exhibited completely different dissolution 
behavior compared to that observed with the PRX-HPMC nanofibers (Figure 
25) (IV). The in vitro drug release profiles of PRX-Soluplus® nanofibers were 
found to be also pH and ionic-strength dependent. Considerable dissolution 
improvement of PRX was achieved in acidic conditions (pH 1.2), where almost 
80% of PRX was released after 30 min (Figure 25). Within the corresponding 
interval, less than 40% of pure PRX was found to be dissolved at pH 7.2. At pH 
7.2, the PRX-HPMC nanofibers showed faster dissolution than PRX-Soluplus® 
nanofibers. With the PRX-Soluplus® nanofibers, the drug release rate was 
clearly increased when the dissolution medium was changed to distilled water 
(Figure 25). These findings are in agreement with a recent study by Hughey et 
al. (2013) reporting the effects of kosmotropic salts (anions) on the gel strength 
and solubility behavior of Soluplus®. The authors stated that at the physio-
logically relevant temperature of 37 °C, the cloud point of Soluplus® was 
reached in deionized water and phosphate buffer (pH 6.8) but not in 0.1 N 
hydrochloric acid (pH 1.2) (Hughey et al., 2013). Obviously, this also explains 
the prolonged drug release profile of the Soluplus® nanofibrous mats obtained at 
pH 7.2 (phosphate buffer solution) (Figure 25). The dissolution profiles of 
Soluplus® nanofibers at pH 7.2, however, showed zero-order kinetics and a 
clear increase in the total time of drug release. This result is in agreement with 
the behavior of a water-soluble polymer or of a low molecular weight polymer 
in DDSs, and suggests an erosion-controlled API release mechanism of 
Soluplus® nanofibrous mats (IV).  
 
 
Figure 25. In vitro drug release of electrospun non-woven nanomats of PRX and 
Soluplus® graft copolymer (1:13 w/w ratio) in distilled water, pH 1.2 buffer solution 
and pH 7.2 phosphate buffer at 37 ± 0.5ºC (n = 5) (IV). 
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6. SUMMARY AND CONCLUSIONS 
The main objectives of this thesis were to gain understanding of the amorphi-
zation and physical stabilization of a poorly water-soluble API (piroxicam as a 
model API), to evaluate the validity of ES as a novel technique in fabricating 
the high-energy amorphous solid dispersions (SDs) of a poorly water-soluble 
API, and to gather detailed information on the physicochemical, geometrical 
and dissolution properties of such nanofibrous SDs. The surface morphology, 
solid state and thermal properties of API and potential solid-state interactions 
with the polymer(s) were investigated by scanning electron microscopy (SEM), 
X-ray powder diffraction (XRPD), Raman spectroscopy and differential scan-
ning calorimetry (DSC). Special attention was paid to the geometric properties 
and surface morphology of drug-loaded nanofibers and nanomats by using 
scanning white light interferometry (SWLI) for 3D topography analysis. PRX 
was used as a model poorly water-soluble API, hydroxypropyl methylcellulose 
(HPMC) and a new synthetic graft copolymer, polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol (PCL-PVAc-PEG, Soluplus®) were investigated as 
hydrophilic carrier polymers for ES. 
ES was found to be applicable for the amorphization of poorly water-soluble 
PRX and preparing the high-energy amorphous SDs as supersaturated nanofiber 
matrices. It was possible to reveal the physical stability and dissolution behavior 
of these electrospun nanofibrous matrices, thus, the fabricated nanofiber matri-
ces showed controlled-release (CR) dissolution behavior. The physicochemical 
properties, such as stability and dissolution were dependent on the carrier 
polymer, initial crystalline form of PRX, solvent system and storage conditions 
applied. HPMC and Soluplus® studied as carrier polymers in ES stabilized the 
amorphous state of PRX. XRPD and Raman spectroscopy complemented with 
DSC analysis allowed thorough solid-state characterization of PRX forms and 
solid-state transformations related to the present nanofibers. SWLI was found to 
be the method of choice for rapid non-contacting and non-destructive 3D 
surface topographic analysis of nanofibrous mats. SWLI provided nanometer 
depth resolution without sample preparation and the method was for the first 
time used for characterizing the orientation, layer thickness, cross-sectional 
shape, flattening and the surface morphology of electrospun single nanofibers 
and nanomats. Such analysis is important because the topography characteristics 
affect the performance of nanofibrous mats in pharmaceutical and biomedical 
applications. The two solid-state forms of PRX, anhydrate and monohydrate, 
showed different solubility and dissolution rate at pH 1.2 (HCl/KCl buffer 
solution), pH 5.6 (distilled water) and pH 7.2 (phosphate buffer solution). The 
solubility and dissolution rate of amorphous PRX loaded in electrospun nano-
fibers were greatly dependent on the physiochemical properties of a carrier 
polymer. 
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On the basis of the present results, the following conclusions can be drawn: 
1. ES can be used for the amorphization of poorly water-soluble PRX and for 
fabricating supersaturated CR nanofibrous matrices loaded with PRX. The 
properties of such CR–SD nanofibers, e.g. the physical stability and dis-
solution, are dependent on the carrier polymer, initial crystalline form of 
PRX, solvent system and storage conditions.  
2. X-ray powder diffraction (XRPD) and Raman spectroscopy complemented 
with differential scanning calorimetry (DSC) analysis permit thorough solid-
state characterization of PRX forms and its transformations in the electro-
spun nanofibers. The hydrophilic carrier polymers used in ES are also 
applicable in stabilizing the amorphous state of PRX in nanofibers. 
3. Scanning white light interferometry (SWLI) permits a rapid non-contacting 
and non-destructive 3D surface topographic analysis of pharmaceutical drug-
loaded nanofibrous mats. The method provides nanometer depth resolution 
without sample preparation. It can be used for characterizing the orientation, 
layer thickness, cross-sectional shape, flattening and the surface morphology 
of electrospun single nanofibers and nanomats.  
4. The two solid-state forms of PRX, anhydrate and monohydrate, show 
different solubility and dissolution rate at pH 1.2 (HCl/KCl buffer solution), 
pH 5.6 (distilled water) and pH 7.2 (phosphate buffer solution). This is due 
to their different molecular structures and ionization of the molecules.  
5. The solubility and dissolution rate of amorphous PRX loaded in electrospun 
nanofibers are greatly dependent on the physicochemical properties of a 
carrier polymer.  
 
55 
7. REFERENCES 
Aaltonen, J., P. Heinänen, L. Peltonen, H. Kortejärvi, V. P. Tanninen, L. Christiansen, 
J. Hirvonen, J. Yliruusi, and J. Rantanen, 2006, In situ measurement of solvent-
mediated phase transformations during dissolution testing. J Pharm Sci, v. 95, p. 
2730–2737. 
Agarwal, S., J. H. Wendorff, and A. Greiner, 2008, Use of electrospinning technique for 
biomedical applications. Polymer, v. 49, p. 5603–5621. 
Airaksinen, S., M. Karjalainen, N. Kivikero, S. Westermarck, A. Shevchenko, J. 
Rantanen, and J. Yliruusi, 2005, Excipient selection can significantly affect solid-
state phase transformation in formulation during wet granulation. AAPS 
PharmSciTech, v. 6, p. E311–322. 
Amidon, G. L., H. Lennernas, V. P. Shah, and J. R. Crison, 1995, A theoretical basis for 
a biopharmaceutic drug classification: the correlation of in vitro drug product 
dissolution and in vivo bioavailability. Pharm Res, v. 12, p. 413–420. 
Banerjee, R., H. Chakraborty, and M. Sarkar, 2003, Photophysical studies of oxicam 
group of NSAIDs: piroxicam, meloxicam and tenoxicam. Spectrochim Acta A Mol 
Biomol Spectrosc, v. 59, p. 1213–1222. 
Basf, 2010, Soluplus, Technical Information, p. 1–8. 
Bates, T. R., 1969, Dissolution characteristics of reserpine-polyvinylpyrrolidone co-
precipitates. J Pharm Pharmacol, v. 21, p. 710–712. 
Bernstein, J., 2002, Polymorphism in Molecular Crystals. IUCr monographs on 
crystallography. Oxford, New York: Oxford University Press, 428 p. 
Bhardwaj, N., and S. C. Kundu, 2010, Electrospinning: A fascinating fiber fabrication 
technique. Biotechnol Adv, v. 28, p. 325–347. 
Bhattarai, N., D. Edmondson, O. Veiseh, F. A. Matsen, and M. Zhang, 2005, 
Electrospun chitosan-based nanofibers and their cellular compatibility. Biomaterials, 
v. 26, p. 6176–6184. 
Bordner, J., J. A. Richards, P. Weeks, and E. B. Whipple, 1984, Piroxicam mono-
hydrate: a zwitterionic form, C15H13N3O4S.H2O. Acta Crystallogr Sect C: Cryst 
Struct Commun, v. 40, p. 989–990. 
Brewster, M. E., G. Verreck, I. Chun, J. Rosenblatt, J. Mensch, A. Van Dijck, M. 
Noppe, A. Ariën, M. Bruining, and J. Peeters, 2004, The use of polymer-based 
electrospun nanofibers containing amorphous drug dispersions for the delivery of 
poorly water-soluble pharmaceuticals. Pharmazie, v. 59, p. 387–391. 
Brittain, H. G., 2009, Theory and Principles of Polymorphic Systems, in H. G. Brittain, 
ed., Polymorphism in Pharmaceutical Solids, v. Drugs and the Pharmaceutical 
Sciences. NY, London: Informa Healthcare, p. 1–23. 
Brittain, H. G., 2012, Polymorphism and solvatomorphism 2010. J Pharm Sci, v. 101, p. 
464–484. 
Brittain, H. G., K. R. Morris, and S. X. M. Boerrigter, 2009, Structural Aspects of 
Solvatomorphic Systems, in H. G. Brittan, ed., Polymorphism in Pharmaceutical 
Solids, v. Drugs and the Pharmaceutical Sciences. NY, London: Informa Healthcare, 
p. 233–280. 
Brough, C., and R. O. Williams, 3rd, 2013, Amorphous solid dispersions and nano-
crystal technologies for poorly water-soluble drug delivery. Int J Pharm, v. 453, p. 
157–166. 
56 
Brouwers, J., M. E. Brewster, and P. Augustijns, 2009, Supersaturating drug delivery 
systems: the answer to solubility-limited oral bioavailability?. J Pharm Sci, v. 98, p. 
2549–2572. 
Chemburkar, S. R., J. Bauer, K. Deming, H. Spiwek, K. Patel, J. Morris, R. Henry, S. 
Spanton, W. Dziki, W. Porter, J. Quick, P. Bauer, J. Donaubauer, B. A. Narayanan, 
M. Soldani, D. Riley, and K. McFarland, 2000, Dealing with the impact of ritonavir 
polymorphs on the late stages of bulk drug process development. Org Process Res 
Dev, v. 4, p. 413–417. 
Chen, M., P. K. Patra, S. B. Warner, and S. Bhowmick, 2007, Role of fiber diameter in 
adhesion and proliferation of NIH 3T3 fibroblast on electrospun polycaprolactone 
scaffolds. Tissue Eng, v. 13, p. 579–587. 
Chew, S. Y., Y. Wen, Y. Dzenis, and K. W. Leong, 2006, The role of electrospinning in 
the emerging field of nanomedicine. Curr Pharm Des, v. 12, p. 4751–4770. 
Chiou, W. L., and S. Riegelman, 1969, Preparation and dissolution characteristics of 
several fast-release solid dispersions of griseofulvin. J Pharm Sci, v. 58, p. 1505–
1510. 
Chiou, W. L., and S. Riegelman, 1971, Pharmaceutical applications of solid dispersion 
systems. J Pharm Sci, v. 60, p. 1281–1302. 
Chronakis, I. S., 2005, Novel nanocomposites and nanoceramics based on polymer 
nanofibers using electrospinning process – A review. J Mater Process Technol, v. 
167, p. 283–293. 
Chung, S., A. K. Moghe, G. A. Montero, S. H. Kim, and M. W. King, 2009, 
Nanofibrous scaffolds electrospun from elastomeric biodegradable poly(L-lactide-
co-ε-caprolactone) copolymer. Biomed Mater, v. 4, p. 015019. 
Costantino, H. R., L. Firouzabadian, C. Wu, K. G. Carrasquillo, K. Griebenow, S. E. 
Zale, and M. A. Tracy, 2002, Protein spray freeze drying. 2. Effect of formulation 
variables on particle size and stability. J Pharm Sci, v. 91, p. 388–395. 
Coupland, J. M., and J. Lobera, 2010, Measurement of steep surfaces using white light 
interferometry. Strain, v. 46, p. 69–78. 
Craig, D. Q., 2002, The mechanisms of drug release from solid dispersions in water-
soluble polymers. Int J Pharm, v. 231, p. 131–144. 
Crowley, M. M., F. Zhang, M. A. Repka, S. Thumma, S. B. Upadhye, S. K. Battu, J. W. 
McGinity, and C. Martin, 2007, Pharmaceutical applications of hot-melt extrusion: 
part I. Drug Dev Ind Pharm, v. 33, p. 909–926. 
de Waard, H., W. L. Hinrichs, M. R. Visser, C. Bologna, and H. W. Frijlink, 2008, 
Unexpected differences in dissolution behavior of tablets prepared from solid 
dispersions with a surfactant physically mixed or incorporated. Int J Pharm, v. 349, 
p. 66–73. 
Dhirendra, K., S. Lewis, N. Udupa, and K. Atin, 2009, Solid dispersions: a review. Pak 
J Pharm Sci, v. 22, p. 234–246. 
Ding, B., H.-Y. Kim, S.-C. Lee, D.-R. Lee, and K.-J. Choi, 2002, Preparation and 
characterization of nanoscaled poly(vinyl alcohol) fibers via electrospinning. Fiber 
Polymer, v. 3, p. 73–79. 
Dow, 2015a, Hydroxypropyl Methylcellulose, Using METHOCEL cellulose ethers for 
controlled release of drugs in hydrophilic matrix systems, The Dow Chemical 
Company. 
Dow, 2015b, Using METHOCEL cellulose ethers for controlled release of drugs in 
hydrophilic matrix systems, Colorcon Inc (US). 
57 
Formhals, A., 1934, Process and apparatus for preparing artificial threads, in U. S. P. 
1975504, ed., http://www.uspto.gov/, USA (July, 2015). 
Formhals, A., 1939, Method of producing artificial fibers, in U. S. P. 2158415, ed., 
http://www.uspto.gov/, USA (July, 2015). 
Formhals, A., 1943, Production of artificial fibers from fiber forming liquids, in U. S. P. 
2323025, ed., http://www.uspto.gov/, USA (July, 2015). 
Formhals, A., 1944, Method and apparatus for spinning, in U. S. P. 234950, ed., 
http://www.uspto.gov/, USA (July, 2015). 
Frenot, A., M. W. Henriksson, and P. Walkenström, 2007, Electrospinning of cellulose-
based nanofibers. J Appl Polym Sci, v. 103, p. 1473–1482. 
Garg, K., and G. L. Bowlin, 2011, Electrospinning jets and nanofibrous structures. 
Biomicrofluidics, v. 5, p. 13403-(1–19). 
Geng, X., O. H. Kwon, and J. Jang, 2005, Electrospinning of chitosan dissolved in 
concentrated acetic acid solution. Biomaterials, v. 26, p. 5427–5432. 
Genina, N., D. Fors, H. Vakili, P. Ihalainen, L. Pohjala, H. Ehlers, I. Kassamakov, E. 
Haeggström, P. Vuorela, J. Peltonen, and N. Sandler, 2012, Tailoring controlled-
release oral dosage forms by combining inkjet and flexographic printing techniques. 
Eu J Pharm Sci, v. 47, p. 615–623. 
Ghasemi-Mobarakeh, L., D. Semnani, and M. Morshed, 2007, A novel method for 
porosity measurement of various surface layers of nanofibers mat using image 
analysis for tissue engineering applications. J Appl Polym Sci, v. 106, p. 2536–2542. 
Grant, D. J. W., 1999, Theory and origin of Polymorphism, in H. G. Brittain, ed., 
Polymorphism in Pharmaceutical Solids, v. Drugs and the Pharmaceutical Solids. 
NY: Marcel Dekker, Inc., p. 1–33. 
Griesser, U. J., 2006, The importance of solvates, in R. Hilfiker, ed., Polymorphism: in 
the pharmaceutical industry. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 
p. 211–233. 
Groth, P., 1906–1919, Chemische krystallographie, Leipzig: Verlag von Wilhelm 
Engelmann. 
Gwak, H. S., J. S. Choi, and H. K. Choi, 2005, Enhanced bioavailability of piroxicam 
via salt formation with ethanolamines. Int J Pharm, v. 297, p. 156–161. 
Haleblian, J., and W. McCrone, 1969, Pharmaceutical applications of polymorphism. J 
Pharm Sci, v. 58, p. 911–929. 
Hancock, B. C., and G. Zografi, 1997, Characteristics and significance of the 
amorphous state in pharmaceutical systems. J Pharm Sci, v. 86, p. 1–12. 
Hanhijärvi, K., T. Majava, I. Kassamakov, J. Heinämäki, J. Aaltonen, J. Haapalainen, E. 
Haeggström, and J. Yliruusi, 2010, Scratch resistance of plasticized hydroxypropyl 
methylcellulose (HPMC) films intended for tablet coatings. Eur J Pharm Biopharm, 
v. 74, p. 371–376. 
Hardung, H., D. Djuric, and S. Ali, 2010, Combining HME & solubilization: Soluplus® 
- the solid solution. Drug Deliv Technol, v. 10, p. 20–27. 
Hu, X., S. Liu, G. Zhou, Y. Huang, Z. Xie, and X. Jing, 2014, Electrospinning of 
polymeric nanofibers for drug delivery applications. J Control Release, v. 185, p. 
12–21. 
Huang, L. Y., C. Branford-White, X. X. Shen, D. G. Yu, and L. M. Zhu, 2012, Time-
engineeringed biphasic drug release by electrospun nanofiber meshes. Int J Pharm, 
v. 436, p. 88–96. 
Huang, Y., and W.-G. Dai, 2014, Fundamental aspects of solid dispersion technology 
for poorly soluble drugs. Acta Pharm Sinica B, v. 4, p. 18–25. 
58 
Huang, Z.-M., Y.-Z. Zhang, M. Kotaki, and S. Ramakrishna, 2003, A review on 
polymer nanofibers by electrospinning and their applications in nanocomposites. 
Compos Sci Technol, v. 63, p. 2223–2253. 
Hughey, J. R., J. M. Keen, D. A. Miller, K. Kolter, N. Langley, and J. W. McGinity, 
2013, The use of inorganic salts to improve the dissolution characteristics of tablets 
containing Soluplus(R)-based solid dispersions. Eur J Pharm Sci, v. 48, p. 758–766. 
Ignatious, F., L. Sun, C. P. Lee, and J. Baldoni, 2010, Electrospun nanofibers in oral 
drug delivery. Pharm Res, v. 27, p. 576–588. 
Jachowicz, R., 1987, Dissolution rates of partially water-soluble drugs from solid 
dispersion systems. I. Prednisolone. Int J Pharm, v. 35, p. 1–5. 
Janković, B., J. Pelipenko, M. Škarabot, I. Muševič, and J. Kristl, 2013, The design 
trend in tissue-engineering scaffolds based on nanomechanical properties of 
individual electrospun nanofibers. Int J Pharm, v. 455, p. 338–347. 
Jannesari, M., J. Varshosaz, M. Morshed, and M. Zamani, 2011, Composite poly(vinyl 
alcohol)/poly(vinyl acetate) electrospun nanofibrous mats as a novel wound dressing 
matrix for controlled release of drugs. Int J Nanomedicine, v. 6, p. 993–1003. 
Janssens, S., H. N. de Armas, J. P. Remon, and G. Van den Mooter, 2007, The use of a 
new hydrophilic polymer, Kollicoat IR, in the formulation of solid dispersions of 
Itraconazole. Eur J Pharm Sci, v. 30, p. 288–294. 
Janssens, S., and G. Van den Mooter, 2009, Review: physical chemistry of solid 
dispersions. J Pharm Pharmacol, v. 61, p. 1571–1586. 
Javadzadeh, Y., M. R. Siahi-Shadbad, M. Barzegar-Jalali, and A. Nokhodchi, 2005, 
Enhancement of dissolution rate of piroxicam using liquisolid compacts. Farmaco, 
v. 60, p. 361–365. 
Jayakumar, R., M. Prabaharan, S. V. Nair, and H. Tamura, 2010, Novel chitin and 
chitosan nanofibers in biomedical applications. Biotechnol Adv, v. 28, p. 142–150. 
Jayaraman, K., M. Kotaki, Y. Zhang, X. Mo, and S. Ramakrishna, 2004, Recent 
advances in polymer nanofibers. J Nanosci Nanotechnol, v. 4, p. 52–65. 
Jinno, J., D. Oh, J. R. Crison, and G. L. Amidon, 2000, Dissolution of ionizable water-
insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci, v. 89, p. 
268–274. 
Jørgensen, A., J. Rantanen, M. Karjalainen, L. Khriachtchev, E. Räsänen, and J. 
Yliruusi, 2002, Hydrate formation during wet granulation studied by spectroscopic 
methods and multivariate analysis. Pharm Res, v. 19, p. 1285–91. 
Karatas, A., N. Yuksel, and T. Baykara, 2005, Improved solubility and dissolution rate 
of piroxicam using gelucire 44/14 and labrasol. Farmaco, v. 60, p. 777–782. 
Karavas, E., E. Georgarakis, and D. Bikiaris, 2006, Application of PVP/HPMC miscible 
blends with enhanced mucoadhesive properties for adjusting drug release in 
predictable pulsatile chronotherapeutics. Eur J Pharm Biopharm, v. 64, p. 115–126. 
Karavas, E., E. Georgarakis, M. P. Sigalas, K. Avgoustakis, and D. Bikiaris, 2007, 
Investigation of the release mechanism of a sparingly water-soluble drug from solid 
dispersions in hydrophilic carriers based on physical state of drug, particle size 
distribution and drug-polymer interactions. Eur J Pharm Biopharm, v. 66, p. 334–
347. 
Kassamakov, I., K. Hanhijärvi, I. Abbadi, J. Aaltonen, H. Ludvigsen, and E. 
Haeggström, 2009, Scanning white-light interferometry with a supercontinuum 
source. Opt Lett, v. 34, p. 1582–1584. 
Kassamakov, I. V., H. O. Seppänen, M. J. Oinonen, E. O. Hæggström, J. M. Österberg, 
J. P. Aaltonen, H. Saarikko, and Z. P. Radivojevic, 2007, Scanning white light 
59 
interferometry in quality control of single-point tape automated bonding. 
Microelectron Eng, v. 84, p. 114–123. 
Kenawy, E.-R., F. Abdel-Hay, M. El-Newehy, and G. E. Wnek, 2009, Processing of 
polymer nanofibers through electrospinning as drug delivery systems. Mater Chem 
Phys, v. 113, p. 296–302. 
Kenawy el, R., G. L. Bowlin, K. Mansfield, J. Layman, D. G. Simpson, E. H. Sanders, 
and G. E. Wnek, 2002, Release of tetracycline hydrochloride from electrospun 
poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release, v. 
81, p. 57–64. 
Kogermann, K., J. Aaltonen, C. J. Strachan, K. Pöllänen, P. Veski, J. Heinämäki, J. 
Yliruusi, and J. Rantanen, 2007, Qualitative in situ analysis of multiple solid-state 
forms using spectroscopy and partial least squares discriminant modeling. J Pharm 
Sci, v. 96, p. 1802–1820. 
Kogermann, K., A. Penkina, K. Predbannikova, K. Jeeger, P. Veski, J. Rantanen, and K. 
Naelapää, 2013, Dissolution testing of amorphous solid dispersions. Int J Pharm, v. 
444, p. 40–46. 
Kogermann, K., P. Veski, J. Rantanen, and K. Naelapää, 2011, X-ray powder 
diffractometry in combination with principal component analysis - a tool for 
monitoring solid state changes. Eur J Pharm Sci, v. 43, p. 278–289. 
Koradia, V., A. F. de Lemos, M. Alleso, H. L. de Diego, M. Ringkjobing-Elema, A. 
Müllertz, and J. Rantanen, 2011, Phase transformations of amlodipine besylate solid 
forms. J Pharm Sci, v. 100, p. 2896–2910. 
Larkin, K. G., 1996, Efficient nonlinear algorithm for envelope detection in white light 
interferometry. J Opt Soc Am A, v. 13, p. 832–843. 
Law, D., W. Wang, E. A. Schmitt, Y. Qiu, S. L. Krill, and J. J. Fort, 2003, Properties of 
rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the 
eutectic microstructure. J Pharm Sci, v. 92, p. 505–515. 
Leuenberger, H., 2002, Spray Freeze-drying – The Process of Choice for Low Water 
Soluble Drug. J Nanoparticle Res, v. 4, p. 111–119. 
Leuner, C., and J. Dressman, 2000, Improving drug solubility for oral delivery using 
solid dispersions. Eur J Pharm Biopharm, v. 50, p. 47–60. 
Leung, V., and F. Ko, 2011, Biomedical applications of nanofibers. Polym Adv Technol, 
v. 22, p. 350–365. 
Li, D., and Y. Xia, 2004, Electrospinning of nanofibers: reinventing the wheel?. Adv 
Mater, v. 16, p. 1151–1170. 
Li, W. J., C. T. Laurencin, E. J. Caterson, R. S. Tuan, and F. K. Ko, 2002, Electrospun 
nanofibrous structure: a novel scaffold for tissue engineering. J Biomed Mater Res, 
v. 60, p. 613–621. 
Li, Z., and C. Wang, 2013, One-Dimensional nanostructures. Electrospinning 
Technique and Unique Nanofibers. SpingerBriefs in Materials. Heidelberg, NY: 
Springer SBM. 
Linn, M., E. M. Collnot, D. Djuric, K. Hempel, E. Fabian, K. Kolter, and C. M. Lehr, 
2012, Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro 
and in vivo. Eur J Pharm Sci, v. 45, p. 336–343. 
Loftsson, T., and M. E. Brewster, 2010, Pharmaceutical applications of cyclodextrins: 
basic science and product development. J Pharm Pharmacol, v. 62, p. 1607–1621. 
Lohani, S., and D. J. W. Grant, 2006, Thermodynamics of polymorphs, in R. Hilfiker, 
ed., Polymorphism: in the pharmaceutical industry. Weinheim: WILEY-VCH 
Verlag GmbH & Co. KGaA, p. 21–42. 
60 
Lombardino, J. G., and J. A. Lowe, 2004, The role of the medicinal chemist in drug 
discovery-then and now. Nat Rev Drug Discov, v. 3, p. 853–862. 
Lu, X., C. Wang, and Y. Wei, 2009, One-dimensional composite nanomaterials: 
synthesis by electrospinning and their applications. Small, v. 5, p. 2349–2370. 
Madani-Grasset, F., N. T. Pham, E. Glynos, and V. Koutsos, 2008, Imaging thin and 
ultrathin organic films by scanning white light interferometry. Mater Sci Eng B, v. 
152, p. 125–131. 
Martindale, 2011, Piroxicam, in S. C. Sweetman, ed., Martindale: The complete drug 
reference, London. Chicago: Pharmaceutical Press, p. 122–123. 
Mayersohn, M., and M. Gibaldi, 1966, New method of solid-state dispersion for 
increasing dissolution rates. J Pharm Sci, v. 55, p. 1323–1324. 
McCrone, W. C., 1965, Polymorphism, in D. Fox, M. M. Labes, and A. Weissberger, 
eds., Physics and chemistry of the organic solid state, v. 2. NY: Wiley Interscience 
Inc., p. 725–767. 
Megelski, S., J. S. Stephens, D. B. Chase, and J. F. Rabolt, 2002, Micro- and 
Nanostructured Surface Morphology on Electrospun Polymer Fibers. 
Macromolecules, v. 35, p. 8456–8466. 
Meinel, A. J., O. Germershaus, T. Luhmann, H. P. Merkle, and L. Meinel, 2012, 
Electrospun matrices for localized drug delivery: current technologies and selected 
biomedical applications. Eur J Pharm Biopharm, v. 81, p. 1–13. 
Miller, D. A., J. W. McGinity, and R. O. Williams III, 2008, Solid dispersion 
technologies, in R. O. Williams III, D. R. Taft, and J. T. McConville, eds., Advanced 
Drug Formulation Design to Optimize Therapeutic Outcomes. Drugs and the 
pharmaceutical sciences. NY: Informa Healthcare USA, Inc., p. 451–491. 
Min, B. M., G. Lee, S. H. Kim, Y. S. Nam, T. S. Lee, and W. H. Park, 2004, 
Electrospinning of silk fibroin nanofibers and its effect on the adhesion and 
spreading of normal human keratinocytes and fibroblasts in vitro. Biomaterials, v. 
25, p. 1289–1297. 
Mit-uppatham, C., M. Nithitanakul, and P. Supaphol, 2004, Ultrafine electrospun 
polyamide-6 fibers: effect of solution conditions on morphology and average fiber 
diameter. Macromol Chem Phys, v. 205, p. 2327–2338. 
Morris, K. R., 1999, Structural aspects of hydrates and solvates, in H. G. Brittain, ed., 
Polymorphism in Pharmaceutical Solids. Drugs and the pharmaceutical science: 
NY: Marcel Dekker, Inc., p. 73–124. 
Muhrer, G., U. Meier, F. Fusaro, S. Albano, and M. Mazzotti, 2006, Use of compressed 
gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: 
Generation of drug microparticles and drug–polymer solid dispersions. Int J Pharm, 
v. 308, p. 69–83. 
Naelapää, K., J. P. Boetker, P. Veski, J. Rantanen, T. Rades, and K. Kogermann, 2012, 
Polymorphic form of piroxicam influences the performance of amorphous material 
prepared by ball-milling. Int J Pharm, v. 429, p. 69–77. 
Nagy, Z. K., A. Balogh, B. Vajna, A. Farkas, G. Patyi, A. Kramarics, and G. Marosi, 
2012, Comparison of electrospun and extruded Soluplus®-based solid dosage forms 
of improved dissolution. J Pharm Sci, v. 101, p. 322–332. 
Naraghi, M., I. Chasiotis, H. Kahn, Y. Wen, and Y. Dzenis, 2007, Novel method for 
mechanical characterization of polymeric nanofibers. Rev Sci Instrum, v. 78, p. 
085108. 
61 
Natu, M. V., H. C. de Sousa, and M. H. Gil, 2010, Effects of drug solubility, state and 
loading on controlled release in bicomponent electrospun fibers. Int J Pharm, v. 397, 
p. 50–58. 
Nyström, M., J. Roine, M. Murtomaa, R. Mohan Sankaran, H. A. Santos, and J. 
Salonen, 2015, Solid state transformations in consequence of electrospraying - A 
novel polymorphic form of piroxicam. Eur J Pharm Biopharm, v. 89, p. 182–189. 
Ohgo, K., C. Zhao, M. Kobayashi, and T. Asakura, 2003, Preparation of non-woven 
nanofibers of Bombyx mori silk, Samia cynthia ricini silk and recombinant hybrid 
silk with electrospinning method. Polymer, v. 44, p. 841–846. 
Okuyama, H., Y. Ikeda, S. Kasai, K. Imamori, K. Takayama, and T. Nagai, 1999, 
Influence of non-ionic surfactants, pH and propylene glycol on percutaneous 
absorption of piroxicam from cataplasm. Int J Pharm, v. 186, p. 141–148. 
Owusu-Ababio, G., N. K. Ebube, R. Reams, and M. Habib, 1998, Comparative 
dissolution studies for mefenamic acid-polyethylene glycol solid dispersion systems 
and tablets. Pharm Dev Technol, v. 3, p. 405–412. 
Palakodaty, S., and P. York, 1999, Phase behavioral effects on particle formation 
processes using supercritical fluids. Pharm Res, v. 16, p. 976–985. 
Paudel, A., Z. A. Worku, J. Meeus, S. Guns, and G. Van den Mooter, 2013, 
Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: 
Formulation and process considerations. Int J Pharm, v. 453, p. 253–284. 
Pelipenko, J., P. Kocbek, B. Govedarica, R. Rošic, S. Baumgartner, and J. Kristl, 2013, 
The topography of electrospun nanofibers and its impact on the growth and mobility 
of keratinocytes. Eur J Pharm Biopharm, v. 84, p. 401–411. 
Pelipenko, J., J. Kristl, R. Rosic, S. Baumgartner, and P. Kocbek, 2012, Interfacial 
rheology: an overview of measuring techniques and its role in dispersions and 
electrospinning. Acta Pharm, v. 62, p. 123–140. 
Persano, L., A. Camposeo, C. Tekmen, and D. Pisignano, 2013, Industrial upscaling of 
electrospinning and applications of polymer nanofibers: a review. Macromol Mater 
Eng, v. 298, p. 504–520. 
Petit, S., and G. Coquerel, 2006, The amorphous state, in R. Hilfiker, ed., 
Polymorphism: in the Pharmaceutical Industry. Weinheim: WILEY-VCH Verlag 
GmbH & Co. KGaA, p. 259–285. 
PhEur, 2015a, Hypromellose, European Pharmacopoeia Online 8.5, Strasbourg: 
Council of Europe, p. 2466–2468. 
PhEur, 2015b, Piroxicam, European Pharmacopoeia Online 8.5, p. 3048–3049. 
Pokharkar, V. B., L. P. Mandpe, M. N. Padamwar, A. A. Ambike, K. R. Mahadik, and 
A. Paradkar, 2006, Development, characterization and stabilization of amorphous 
form of a low Tg drug. Powder Technol, v. 167, p. 20–25. 
Pouton, C. W., 2006, Formulation of poorly water-soluble drugs for oral administration: 
Physicochemical and physiological issues and the lipid formulation classification 
system. Eur J Pharm Sci, v. 29, p. 278–287. 
Prasad, D., H. Chauhan, and E. Atef, 2014, Amorphous stabilization and dissolution 
enhancement of amorphous ternary solid dispersions: combination of polymers 
showing drug–polymer interaction for synergistic effects. J Pharm Sci, v. 103, p. 
3511–3523. 
Reck, G., G. Dietz, G. Laban, W. Günther, G. Bannier, and E. Höhne, 1988, X-ray 
studies on piroxicam modifications. Pharmazie, v. 43, p. 477–481. 
Reck, G., and G. Laban, 1990, Prediction and establishment of a new crystalline 
piroxicam modification. Pharmazie, v. 45, p. 257–259. 
62 
Repka, M. A., S. K. Battu, S. B. Upadhye, S. Thumma, M. M. Crowley, F. Zhang, C. 
Martin, and J. W. McGinity, 2007, Pharmaceutical applications of hot-melt 
extrusion: Part II. Drug Dev Ind Pharm, v. 33, p. 1043–1057. 
Rogers, T. L., 2009, Hypromellose, in R. C. Rowe, P. J. Sheskey, and M. E. Quinn, 
eds., Handbook of Pharmaceutical Excipients. London-Chicago: Pharmaceutical 
Press, p. 326–329. 
Rošic, R., J. Pelipenko, P. Kocbek, S. Baumgartner, M. Bešter-Rogač, and J. Kristl, 
2012a, The role of rheology of polymer solutions in predicting nanofiber formation 
by electrospinning. Eur Polym J, v. 48, p. 1374–1384. 
Rošic, R., J. Pelipenko, J. Kristl, P. Kocbek, and S. Baumgartner, 2012b, Properties, 
engineering and applications of polymeric nanofibers: current research and future 
advances. Chem Biochem Eng Q, v. 26, p. 417–425. 
Savolainen, M., K. Kogermann, A. Heinz, J. Aaltonen, L. Peltonen, C. Strachan, and J. 
Yliruusi, 2009, Better understanding of dissolution behaviour of amorphous drugs 
by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm, v. 
71, p. 71–79. 
Schiffman, J. D., and C. L. Schauer, 2008, A Review: electrospinning of biopolymer 
nanofibers and their applications. Polym Rev, v. 48, p. 317–352. 
Seddon, K. R., 2004, Pseudopolymorph: A polemic. Cryst Growth Des, v. 4, p. 1087–
1087. 
Sekiguchi, K., and N. Obi, 1961, Stuclies on Absorption of Eutectic Mixture. I. A 
Comparison of the Behavior of Eutectic Mixture of Sulfathiazol and that of Ordinary 
Sulfathiazole in Man. Chem Pharm Bull, v. 9, p. 866–872. 
Sekiguchi, K., N. Obi, and Y. Ueda, 1964, Studies on absorption of eutectic mixture. II. 
Absorption of fused conglomerates of chloramphenicol and urea in rabbits. Chem 
Pharm Bull, v. 12, p. 134–144. 
Seo, A., P. Holm, H. G. Kristensen, and T. Schaefer, 2003, The preparation of 
agglomerates containing solid dispersions of diazepam by melt agglomeration in a 
high shear mixer. Int J Pharm, v. 259, p. 161–171. 
Serajuddin, A. T., 1999, Solid dispersion of poorly water-soluble drugs: early promises, 
subsequent problems, and recent breakthroughs. J Pharm Sci, v. 88, p. 1058–1066. 
Sethia, S., and E. Squillante, 2002, Physicochemical characterization of solid 
dispersions of carbamazepine formulated by supercritical carbon dioxide and 
conventional solvent evaporation method. J Pharm Sci, v. 91, p. 1948–1957. 
Shah, S., S. Maddineni, J. Lu, and M. A. Repka, 2013, Melt extrusion with poorly 
soluble drugs. Int J Pharm, v. 453, p. 233–252. 
Sheth, A. R., S. Bates, F. X. Muller, and D. J. W. Grant, 2004a, Polymorphism in 
piroxicam. Cryst Growth Des, v. 4, p. 1091–1098. 
Sheth, A. R., J. W. Lubach, E. J. Munson, F. X. Muller, and D. J. W. Grant, 2005, 
Mechanocromism of piroxicam accompanied by intermolecular proton trensfer 
probed by spectroscopic methods and solid-phase changes. J Am Chem Soc, v. 127 
(18), p. 6641–6651. 
Sheth, A. R., D. Zhou, F. X. Muller, and D. J. Grant, 2004b, Dehydration kinetics of 
piroxicam monohydrate and relationship to lattice energy and structure. J Pharm 
Sci, v. 93, p. 3013–3026. 
Sill, T. J., and H. A. von Recum, 2008, Electrospinning: applications in drug delivery 
and tissue engineering. Biomaterials, v. 29, p. 1989–2006. 
Simons, H. L., 1966, Process and apparatus for producing patterned non-woven fabrics, 
in A. United States Patent 3, ed., http://www.uspto.gov/ (July, 2015). 
63 
Srinivasan, G., and D. H. Reneker, 1995, Structure and morphology of small diameter 
electrospun aramid fibers. Polym Int, v. 36, p. 195–201. 
Stahly, P. G., 2007, Diversity in single- and multiple-component crystals. The search 
for and prevalence of polymorphs and cocrystals. Cryst Growth Des, v. 7(6), p. 
1007–1026. 
Stranska, D., I. Erlebachova, V. Kral, P. Sebek, J. Beranek, A. Dumicic, G. Sedmak, T. 
Chvojka, and a. s. Zentiva, 2014, Drug formulation using API in nanofibers, in E. P. 
Office, ed., https://www.google.co.in/patents/EP2813212A1?cl=en (July, 2015). 
Stulzer, H. K., M. P. Tagliari, A. P. Cruz, M. A. S. Silva, and M. C. M. Laranjeira, 
2008, Compatibility studies between piroxicam and pharmaceutical excipients. 
Pharm Chem J, v. 42, p. 215–219. 
Tachibana, T. and A. Nakamura, 1965, A methode for preparing an aqueous colloidal 
dispersion of organic materials by using water-soluble polymers: dispersion of β-
carotene by polyvinylpyrrolidone. Kolloid-Zeitschrift und Zeitschrift für Polymere, 
v.203, p.130-133. 
Taepaiboon, P., U. Rungsardthong, and P. Supaphol, 2006, Drug-loaded electrospun 
mats of poly(vinyl alcohol) fibres and their release characteristics of four model 
drugs. Nanotechnology, v. 17, p. 2317–2329. 
Tan, E. P. S., and C. T. Lim, 2005, Nanoindentation study of nanofibers. Appl Phys 
Lett, v. 87, p. 123106. 
Tan, E. P. S., and C. T. Lim, 2006, Mechanical characterization of nanofibers – A 
review. Comp Sci Technol, v. 66, p. 1102–1111. 
Taylor, G. I., 1964, Disintegration of Water Drops in an Electric Field. Proceedings of 
the Royal Society A, v. 280, p. 383–387. 
Taylor, G. I., 1969, Electrically Driven Jets. Proceedings of the Royal Society A, v. 313, 
p. 453–475. 
Taylor, L. S., and S. L. Shamblin, 2009, Amorphous solids, in H. G. Brittain, ed., 
Polymorphism in pharmaceutical solids. Drugs and the pharmaceutical sciences, 
NY: Informa Healthcare, p. 587–629. 
Taylor, L. S., and G. Zografi, 1997, Spectroscopic characterization of interactions 
between PVP and indomethacin in amorphous molecular dispersions. Pharm Res, v. 
14, p. 1691–1698. 
Teo, W. E., and S. Ramakrishna, 2006, A review on electrospinning design and 
nanofibre assemblies. Nanotechnology, v. 17, p. R89-R106. 
Timko, R. J., and N. G. Lordi, 1979, Thermal characterization of citric acid solid 
dispersions with benzoic acid and phenobarbital. J Pharm Sci, v. 68, p. 601–605. 
Tran, P. H., T. T. Tran, J. B. Park, and B. J. Lee, 2011, Controlled release systems 
containing solid dispersions: strategies and mechanisms. Pharm Res, v. 28, p. 2353–
2378. 
USP28-NF23, 2005, The United States Pharmacopeia, The National Formulary 
(USP28-NF23). Rockville, Md, USA: United States Pharmacopoeial Convention, p. 
2412. 
Van den Mooter, G., I. Weuts, T. De Ridder, and N. Blaton, 2006, Evaluation of Inutec 
SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. 
Int J Pharm, v. 316, p. 1–6. 
van Drooge, D. J., W. L. Hinrichs, and H. W. Frijlink, 2004, Anomalous dissolution 
behaviour of tablets prepared from sugar glass-based solid dispersions. J Control 
Release, v. 97, p. 441–452. 
64 
van Drooge, D. J., W. L. Hinrichs, M. R. Visser, and H. W. Frijlink, 2006, 
Characterization of the molecular distribution of drugs in glassy solid dispersions at 
the nano-meter scale, using differential scanning calorimetry and gravimetric water 
vapour sorption techniques. Int J Pharm, v. 310, p. 220–229. 
Vasconcelos, T., B. Sarmento, and P. Costa, 2007, Solid dispersions as strategy to 
improve oral bioavailability of poor water soluble drugs. Drug Discov Today, v. 12, 
p. 1068–1075. 
Verheyen, S., N. Blaton, R. Kinget, and G. Van den Mooter, 2002, Mechanism of 
increased dissolution of diazepam and temazepam from polyethylene glycol 6000 
solid dispersions. Int J Pharm, v. 249, p. 45–58. 
Verreck, G., I. Chun, J. Peeters, J. Rosenblatt, and M. E. Brewster, 2003a, Preparation 
and characterization of nanofibers containing amorphous drug dispersions generated 
by electrostatic spinning. Pharm Res, v. 20, p. 810–817. 
Verreck, G., I. Chun, J. Rosenblatt, J. Peeters, A. V. Dijck, J. Mensch, M. Noppe, and 
M. E. Brewster, 2003b, Incorporation of drugs in an amorphous state into 
electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J 
Control Release, v. 92, p. 349–360. 
Vilhelmsen, T., H. Eliasen, and T. Schaefer, 2005, Effect of a melt agglomeration 
process on agglomerates containing solid dispersions. Int J Pharm, v. 303, p. 132–
142. 
Vippagunta, S. R., H. G. Brittain, and D. J. Grant, 2001, Crystalline solids. Adv Drug 
Deliv Rev, v. 48, p. 3–26. 
Vippagunta, S. R., Z. Wang, S. Hornung, and S. L. Krill, 2007, Factors affecting the 
formation of eutectic solid dispersions and their dissolution behavior. J Pharm Sci, 
v. 96, p. 294–304. 
Vo, C. L., C. Park, and B. J. Lee, 2013, Current trends and future perspectives of solid 
dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm, v. 85, p. 
799–813. 
Vrečer, F., S. Srčič, and J. Šmid-Korbar, 1991, Investigation of piroxicam 
polymorphism. Int J Pharm, v. 68, p. 35–41. 
Vrečer, F., M. Vrbinc, and A. Meden, 2003, Characterization of piroxicam crystal 
modifications. Int J Pharm, v. 256, p. 3–15. 
Vynckier, A.-K., L. Dierickx, J. Voorspoels, Y. Gonnissen, J. P. Remon, and C. 
Vervaet, 2014, Hot-melt co-extrusion: requirements, challenges and opportunities 
for pharmaceutical applications. J Pharm Pharmacol, v. 66, p. 167–179. 
Wagenaar, B. W., and B. W. Müller, 1994, Piroxicam release from spray-dried 
biodegradable microspheres. Biomaterials, v. 15, p. 49–54. 
Wang, X., A. Michoel, and G. Van den Mooter, 2005, Solid state characteristics of 
ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int J 
Pharm, v. 303, p. 54–61. 
Wendorff, J. H., S. Agarwal, and A. Greiner, 2012, Electrospinning: Materials, 
Processing, and Applications. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 
242 p. 
Won, D.-H., M.-S. Kim, S. Lee, J.-S. Park, and S.-J. Hwang, 2005, Improved 
physicochemical characteristics of felodipine solid dispersion particles by 
supercritical anti-solvent precipitation process. Int J Pharm, v. 301, p. 199–208. 
Wu, K., J. Li, W. Wang, and D. A. Winstead, 2009, Formation and characterization of 
solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and 
precipitation with compressed antisolvent. J Pharm Sci, v. 98, p. 2422–2431. 
65 
Yao, W.-W., T.-C. Bai, J.-P. Sun, C.-W. Zhu, J. Hu, and H.-L. Zhang, 2005, 
Thermodynamic properties for the system of silybin and poly(ethylene glycol) 6000. 
Thermochim Acta, v. 437, p. 17–20. 
Yoshioka, M., B. C. Hancock, and G. Zografi, 1994, Crystallization of indomethacin 
from the amorphous state below and above its glass transition temperature. J Pharm 
Sci, v. 83, p. 1700–1705. 
Yu, D.-G., L.-M. Zhu, K. White, and C. Branford-White, 2009, Electrospun nanofiber-
based drug delivery systems. Health, v. 1, p. 67–75. 
Yu, L., 2001, Amorphous pharmaceutical solids: preparation, characterization and 
stabilization. Adv Drug Deliv Rev, v. 48, p. 27–42. 
Yüksel, N., A. Karatas, Y. Ozkan, A. Savaser, S. A. Ozkan, and T. Baykara, 2003, 
Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro 
and in vivo evaluation. Eur J Pharm Biopharm, v. 56, p. 453–459. 
Zahedi, P., I. Rezaeian, S.-O. Ranaei-Siadat, S.-H. Jafari, and P. Supaphol, 2010, A 
review on wound dressings with an emphasis on electrospun nanofibrous polymeric 
bandages. Polym Adv Technol, v. 21, p. 77–95. 
Zeleny, J., 1914, The electrical discharge from liquid points, and a hydrostatic method 
of measuring the electric intensity at their surfaces. Phys Rev, v. 3, p. 69–91. 
Zhang, G. G., D. Law, E. A. Schmitt, and Y. Qiu, 2004, Phase transformation 
considerations during process development and manufacture of solid oral dosage 
forms. Adv Drug Deliv Rev, v. 56: Netherlands, p. 371–390. 
Zhang, Y. Z., B. Su, J. Venugopal, S. Ramakrishna, and C. T. Lim, 2007, Biomimetic 
and bioactive nanofibrous scaffolds from electrospun composite nanofibers. Int J 
Nanomedicine, v. 2, p. 623–638. 
Zimmermann, A., F. Tian, H. Lopez de Diego, M. Ringkjobing Elema, J. Rantanen, A. 
Müllertz, and L. Hovgaard, 2009, Influence of the solid form of siramesine 
hydrochloride on its behavior in aqueous environments. Pharm Res, v. 26, p. 846–
854. 
Zong, X., K. Kwangsok, D. Fang, S. Ran, B. S. Hsiao, and B. Chu, 2002, Structure and 
process relationship of electrospun bioabsorbable nanofiber membranes. Polymer, v. 
43, p. 4403–4412. 
 
66 
8. SUMMARY IN ESTONIAN 
Uued võimalused vees halvasti lahustuvate raviainete amorfse vormi 
saamiseks ja füüsikaliseks stabiliseerimiseks ning nende 
lahustumiskäitumise uurimine 
 
Sissejuhatus 
Juba XIX sajandil märkasid keemikud, et ühe keemilise aine või ühendi kris-
tallid võivad olla erineva kujuga ja sellest tulenevalt ka erinevate füüsikaliste 
omadustega (sulamistemperatuur, lahustumiskiirus jm). Nähtust hakati nime-
tama polümorfismiks ja vastavaid ühendeid polümorfideks (Brittain, 2009; 
Grant, 1999). Selle nähtuse olulisust keemias ja eriti farmaatsias mõisteti juba 
XX sajandi keskpaigas (Haleblian and McCrone, 1969; McCrone, 1965). Kui 
ühe keemilise ühendi struktuuri on kaasatud ka lahusti molekulid, siis nime-
tatakse selliseid ühendeid solvaatideks ja nähtust solvatomorfismiks. Juhul, kui 
solvendiks on vesi, siis hüdraatideks (Brittain et al., 2009; Morris, 1999; 
Seddon, 2004). Paljud raviained võivad eksisteerida erinevates tahketes polü-
morfsetes või solvaatsetes vormides ja ka amorfses olekus. Kuna kõigil neil 
vormidel on erinev sisemine kristallstruktuur ja vabaenergia, siis on neil ka 
erinevad füsikokeemilised omadused, mis mõjutavad oluliselt raviaine käitumist 
organismis. Neist kõige olulisemad ravimpreparaadi seisukohast on raviaine 
lahustuvus ja lahustumiskiirus. Tavaliselt on üks polümorf kindla temperatuuri 
ja rõhu väärtuse juures termodünaamiliselt kõige püsivam ja teised vormid 
(nimetatud ka metastabiilseteks vormideks) muutuvad vabaenergia vähenemise 
tõttu aja jooksul kõige stabiilsemaks vormiks. Amorfsed ained on kõige eba-
stabiilsemad tahke aine vormid ja nende puhul on tegemist mittekristalliliste 
ainetega, millel puudub kindel kolmedimensionaalne kristallstruktuur ja mole-
kulide järjestatus. Kuigi varasemas kirjanduses on eksitavalt amorfset ainet 
käsitletud ka kui ühte polümorfset vormi (Haleblian and McCrone, 1969; Petit 
and Coquerel, 2006). Eristatakse aineid, mis on oma olemuselt amorfsed ja 
neid, mis on erinevate võtetega amorfsesse olekusse viidud. Neid viimaseid 
käsitletakse ka tänapäeval siiski tahke aine ühe vormina (Taylor and Shamblin, 
2009). Tänu oma kristallvormi puudumisele ja kõrgele siseenergiale lahustub 
amorfne raviaine kõige kiiremini ja tema lahustuvus on reeglina teistest kristall-
vormidest suurem. Samuti on amorfse vormi kõrge siseenergia tema suure eba-
stabiilsuse põhjuseks ning amorfsed ained võivad kergesti rekristalliseeruda. 
Sellise rekristalliseerumise tagajärjel võib oluliselt muutuda raviaine lahustu-
vus, lahustumiskiirus ja biosaadavus organismis (Lohani and Grant, 2006). 
Farmaatsias on kasutusel mitmeid võimalusi amorfsete tahkete ainete saamiseks 
nagu näiteks külmutus- või pihustuskuivatamine, peenestamine, märg granulee-
rimine jne, kuid saadud amorfne tahke aine on oluliselt vähem stabiilne, kui 
tema vastav kristallvorm (Yu, 2001).  
Kaasajal omavad ca 80% turul olevatest raviainetest polümorfseid või 
solvaatvorme (Lohani and Grant, 2006; Stahly, 2007) ja samas sisaldavad 
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umbes 40% turustatavatest ning ca 90% arendamisel olevatest uutest ravim-
preparaatidest vees halvasti lahustuvaid raviaineid (Loftsson and Brewster, 
2010). Seega, kuna halb või vähene vesi-lahustuvus on ravimpreparaatide val-
mistamisel üks võtmeküsimusi, eriti Biofarmatseutilise klassifikatsiooni süs-
teemi (BSC) II klassi raviainete puhul, kus lahustumiskiirus on imendumist 
limiteerivaks faktoriks, on raviainete lahustuvuse, lahustumiskiiruse ja seega ka 
biosaadavuse suurendamine üks olulisi teemasid farmaatsiatööstuse jaoks. 
Piroksikaam (PRX) on oksikaamide gruppi kuuluv vees halvasti lahustuv 
raviaine, mida sageli kasutatakse tema huvitavate füsikokeemiliste omaduste 
tõttu mudelraviainena teaduslikus uurimistöös. Tema tahke aine erinevad 
vormid (PRX amorfne vorm ja veevabad kristallvormid I (PRXAH), II, III ning 
monohüdraatvorm, PRXMH) on kirjanduses hästi dokumenteeritud ning 
omavad lisaks erinevale kristalli kujule ka erinevat värvust ja seetõttu on tahke 
aine vormide üleminek ühest vormist teise sageli visuaalselt jälgitav (Koger-
mann et al., 2007; Nyström et al., 2015; Sheth et al., 2005; Vrečer et al., 2003). 
PRX kuulub BCS järgi II klassi, kui halvasti lahustuv ja hästi imenduv raviaine 
(Amidon et al., 1995; Gwak et al., 2005; Lombardino and Lowe, 2004). Et PRX 
omab kahte pKa väärtust (1,86 ja 5,46), siis võib ta seetõttu käituda nii happe 
kui alusena vastavalt keskkonnale (Banerjee et al., 2003; Jinno et al., 2000). 
Tahkete dispersioonidena tuntakse täna farmaatsias süsteeme, kus tahke 
raviaine on dispergeeritud tahkes inertses kandjas, kus pole detekteeritav teine 
faas. Raviaine võib olla tahkes dispersioonis kas dispergeeritult kandjas mole-
kulaarsel tasemel (tahke lahus) või amorfsete osakestena, või siis kristalliliste 
osakestena kandjas, mis võib omakorda olla kas kristalliline või amorfne (Miller 
et al., 2008; Vo et al., 2013). Tahked dispersioonid on osutunud edukaks vees 
halvasti lahustuvate raviainete lahustuvuse parandamisel ja nende biosaadavuse 
suurendamisel, kuid endiselt on probleeme raviaine püsivuse tagamisega tahke-
te dispersioonide tootmisprotsessi jooksul ja säilitamisel ning see võib oluliselt 
muuta raviaine biosaadavust organismis (Brouwers et al., 2009; Janssens and 
Van den Mooter, 2009; Leuner and Dressman, 2000; Vo et al., 2013).  
Elektrospinnimine (ES) on tahkete polümeersete nanofiibrite valmistamise 
tehnika, mida tuntakse juba möödunud sajandi algusest (Zeleny, 1914). Kaas-
ajal on tehnikat täiustatud ja ES-l võib saada nanofiibreid peaaegu kõigist 
polümeeridest, kui valida sobiv solventsüsteem ning ES tingimused. Raviainete 
viimine ES polümeerilahuste koostisesse on uus võimalus raviainete lahus-
tuvuse ja seega ka biosaadavuse muutmiseks. Moodustuvates tahketes disper-
sioonides on raviaine sageli dispergeeritud molekulaarsel tasemel või muudab 
inkorporeerimise protsessi ajal oma tahke aine vormi (Huang and Dai, 2014; 
Nagy et al., 2012; Rošic et al., 2012b). 
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Töö eesmärgid 
Töö eesmärgiks oli saada teadmisi vees halvasti lahustuva raviaine, piroksi-
kaami (PRX) amorfse vormi tekkest ja stabiilsusest elektrospinnimisel saadud 
nanofiibrites ning PRX kristallvormide lahustumiskäitumisest.  
Täpsemad töö eesmärgid olid: 
‒ kasutada elektrospinnimist kui uut võimalust raviaine kontrollitud vaba-
nemisega tahke amorfse dispersiooni saamiseks halvasti lahustuvast ravi-
ainest, PRX ja hüdrofiilsetest polümeeridest; 
‒ kasutada skaneeriva valge valgusega interferomeetriat (SWLI) kui potent-
siaalset uut meetodit, mis ei vaja proovi ettevalmistamist, elektrospinnitud 
raviaine nanofiiber-võrgu pinnaomaduste kiireks, kontaktivabaks ja kahju-
tuks 3D analüüsimiseks; 
‒ selgitada välja hüdrofiilsete polümeeride, eriti uue sünteetilise pook-kopo-
lümeeri Soluplus® (PCL-PVAc-PEG, polüvinüülkaprolaktaam-polüvinüül-
atsetaat-polüetüleenglükool pook-kopolümeer) ja solventsüsteemide mõju 
raviainet sisaldavate nanofiibrite stabiilsusele ja raviaine tahke vormi 
muutustele neis; 
‒ teha täpsemalt kindlaks pH mõju PRX kahe tahke vormi (veevaba PRXAH 
ja monohüdraadi PRXMH) lahustuvusele ja lahustumiskiirusele; 
‒ saada teadmisi vees halvasti lahustuva raviaine PRX vabanemis- ja lahus-
tumiskiirusest polümeersetest elektrospinnitud nanofiibritest.  
 
 
Materjalid Ja meetodid 
Uuringus kasutati mudelraviainena vees halvasti lahustuvat piroksikaami, PRX 
[nii veevaba piroksikaami vorm I (PRXAH I) kui monohüdraatvormi (PRXMH), 
mis valmistati ise]. Hüdrofiilsete polümeeridena kasutati hüdroksüpropüül-
metüültselluloosi (HPMC) keskmise molekulmassiga 100 000 Da (MethocelTM 
K100M Premium CR) ja pook-kopolümeeri Soluplus® (PCL-PVAc-PEG, 
polüvinüülkaprolaktaam-polüvinüülatsetaat-polüetüleenglükool pook-kopolü-
meer). Solventidena elektrospinnimisel kasutati vastavalt 1,1,1,3,3,3-heksafluoro-
2-propanooli (HFIP) ja atsetooni. 
Uuringus kasutatud meetodite hulka kuulusid elektrospinnimine ning saadud 
nanofiibrite suuruse ja kuju uurimine skaneeriva elektronmikroskoobi (SEM) 
ning pinna 3D topograafia uurimine skaneeriva valge valguse interferomeetri 
(SWLI) abil. Raviaine füsikokeemilisi omadusi ning vormide vahelisi muutusi 
säilitamisel uuriti kasutades erinevaid meetodeid: Raman spektroskoopiat, 
pulber-röntgendifraktomeetriat (XRPD) ja diferentsiaalset skaneerivat kalori-
meetriat (DSC).  
PRX vormide ja PRXi sisaldavate nanofiibrite lahustumiskiiruse uurimiseks 
kasutati in vitro dissolusiooniteste vastavalt USP 28 korvikeste meetodile 
kasutades kolme erinevat lahustumiskeskkonda: pH 1,2 (HCl/KCl puhverlahus), 
pH 5,6 (destilleeritud vesi) ja pH 7,2 (fosfaatpuhver). Nanofiiber-võrgustik viidi 
korvikestesse kas pakitult kõvadesse želatiinkapslitesse või lahtiselt. 
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Uuringu põhitulemused 
Elektrospinnimine sobib vees halvasti lahustuva raviaine, piroksikaami (PRX) 
amorfse vormi saamiseks. Pulber-röntgendidraktomeetria (XRPD), Raman 
spektroskoopia ja diferentsiaalse skaneeriva kalorimeetria (DSC) tulemused kin-
nitasid, et erinevate hüdrofiilsete polümeeridega (HPMC ja Soluplus®) elektro-
spinnimisel saadud nanofiibrites moodustub üleküllastunud tahke dispersioon, 
milles PRX püsib amorfses vormis nii külmkapitemperatuuril (LT) 6–8º C kui ka 
toatemperatuuril (RT) 22±2º C ja 0%-lise suhtelise niiskuse (RH) juures kuni 6 
kuud. Moodustunud üleküllastunud tahkete dispersioonide omadused, nagu 
füüsikaline stabiilsus ja lahustumine, on sõltuvuses nii kasutatud polümeerist, 
PRX algsest kristallivormist, kasutatud solvendist (solventsüsteemist) ja säilita-
mistingimustest. Kõrgem temperatuur ja suurem õhuniiskus ning suurem PRX 
kontsentratsioon nanofiibrites viivad kiirema raviaine kristallvormi muutuseni.  
SEM võimaldab saadud SEM piltidelt näha tekkinud nanofiibrite kuju, 
homogeensust ning mõõta nende diameetrit, kuid hinnata tekkinud nanofiibri 
pinnastruktuuri ja saada 3D ettekujutust on raskem. Ka vajab SEM uuring 
proovide ettevalmistamist (kullaga katmist) ning seetõttu on aja- ning töö-
mahukas. SWLI on kiirelt kasutatav ilma eelneva täiendava uuritava proovi 
ettevalmistuseta, see on kontaktivaba ja kahjutu nanomeeter-skaalas resolutsioo-
niga meetod pinna kolmedimensionaalseks (3D) topograafiliseks analüüsiks. 
SWLI meetodit kasutati esmakordselt üksiku elektrospinnitud nanofiibri ja 
nanofiiber-võrgustiku orientatsiooni, kihi paksuse, ristlõike kuju ja pinna mor-
foloogia uurimiseks. Selline uuring on oluline, kuna topograafilised omadused 
mõjutavad nanofiiber-võrgustike kasutatavust farmaatsias ja biomeditsiinis.  
PRX-i kaks tahke aine vormi, veevaba vorm (PRXAH) ning PRX mono-
hüdraat vorm (PRXMH), omavad erinevat lahustuvust ning lahustumiskiirust 
erinevates keskkondades: pH 1,2 (HCl/KCl puhverlahuses), pH 5,6 (destil-
leeritud vees) ja pH 7,2 (fosfaatpuhvris). PRXAH omab suuremat lahustuvust 
kõigis uuritud keskkondades võrreldes PRXMH-ga (p<0,05), vaid katse alguses 
pH 7,2 ja pH 1,2 juures oli PRXMH lahustumiskiirus suurem kui PRXAH-l. 
Elektrospinnitud nanofiibrites oleva PRX amorfse vormi lahustuvus ja 
lahustumiskiirus on otseses sõltuvuses vastava polümeeri füsikokeemilistest 
omadustest. Nii on PRX/HPMC nanofiibritest vabaneva PRX lahustumiskiirus 
vähem sõltuvuses lahustumiskeskkonna pH-st kui puhta PRXAH lahustumise 
korral, olles pH 1,2 juures vaid veidi väiksem kui pH 7,2 juures. PRX vabaneb 
HPMC nanofiibritest aeglaselt, mis teeb elektrospinnitud nanofiiber-võrgustiku 
sobivaks raviainet prolongeeritult (reguleeritult) vabastava ravimvormi valmis-
tamiseks. Ka Soluplus®-i pook-kopolümeerist vabaneb PRX amorfne vorm 
aeglaselt, kuid erinevalt PRX/HPMC nanofiibritest on PRX/Soluplus® nano-
fiibritest vabaneva PRX lahustumiskiirus kõige väikesem pH 7,2 juures ning 
kõige suurem pH 1,2 juures.  
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Järeldused: 
1.  Elektrospinnimist saab kasutada vees halvasti lahustuva raviaine, piroksi-
kaami (PRX) amorfse vormi saamiseks. Saadud nanofiiber-võrgustikud on 
PRX kontrollitult vabastavad üleküllastunud tahked dispersioonid, mille 
omadused nagu füüsikaline stabiilsus ja lahustumine on sõltuvuses kasutatud 
polümeerist, PRX algsest kristallvormist, kasutatud solventsüsteemist ja 
säilitamise tingimustest. 
2.  Pulber-röntgendifraktomeetriline (XRPD) ja Raman spektroskoopiline ja 
täiendav diferentsiaalne skaneeriv kalorimeetriline (DSC) analüüs võimal-
davad määrata PRX vorme ja nende muutumist elektrospinnitud nano-
fiibrites. Kasutatud polümeerid stabiliseerivad PRX amorfse oleku nano-
fiibrites. 
3.  Skaneeriv valge valguse interferomeetria (SWLI) on kontaktivaba ja kahjutu 
nanomeeter-skaalas resolutsiooniga meetod pinna kolmemõõtmeliseks (3D) 
topograafiliseks analüüsiks, mida saab kasutada kiiresti ilma eelneva proovi 
ettevalmistuseta. SWLI meetodit saab kasutada üksiku elektrospinnitud 
nanofiibri ja nanofiiber-võrgustiku orientatsiooni, kihi paksuse, ristlõike kuju 
ja pinna morfoloogia uurimiseks. Selline uuring on oluline, kuna topo-
graafilised omadused mõjutavad nanofiiber-võrgustike kasutatavust far-
maatsias ja biomeditsiinis. 
4. PRX-i kaks kristallivormi, veevaba vorm I ning monohüdraat, omavad 
erinevat lahustuvust ning lahustumiskiirust pH 1,2 (HCl/KCl puhverlahuses), 
pH 5,6 (destilleeritud vees) ja pH 7,2 (fosfaatpuhvris) oma erineva mole-
kulaarse struktuuri ja ionisatsiooni tõttu. 
5.  Elektrospinnitud nanofiibrites oleva amorfse PRX lahustuvus ja lahustumis-
kiirus on otseses sõltuvuses kasutatud polümeeri omadustest.  
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